

Supporting Information

α_2 -Adrenoceptor Antagonists: Synthesis, Pharmacological Evaluation and Molecular Modelling Investigation of Pyridino Guanidine/2-Aminoimidazoline and their Derivatives

Brendan Kelly,^a Michela McMullan,^a Carolina Muguruza,^b Jorge E. Ortega,^b J. Javier Meana,^b Luis F. Callado,^b Isabel Rozas,^a

^a School of Chemistry, Trinity Biomedical Sciences Institute, University of Dublin, Trinity College, 152-160 Pearse St., Dublin 2, Ireland

^b Department of Pharmacology, Faculty of Medicine, University of the Basque Country, 48940-Leioa, Bizkaia, Spain, and CIBER of Mental Health, CIBERSAM, Spain

Contents

Contents	S1
1. Preparation of <i>N</i> -(<i>tert</i> -butoxycarbonyl)- <i>N'</i> -substituted thioureas	S2
2. Preparation of <i>S</i> -methyl- <i>N</i> -substituted dithiocarbamates	S5
3. Preparation of non-commercial starting amines	S8
4. Synthesis and Characterisation of Boc-protected/neutral guanidine intermediates.....	S11
5. Yields obtained for all compounds prepared	S23
6. NMR spectra of final hydrochloride salts.....	S28
7. HPLC spectra of final hydrochloride salts.....	S67
8. Preparation of membranes	S106
9. Analysis of binding data	S106
10. Drugs used in pharmacology experiments	S106
11. [³⁵ S]GTP γ S functional assays results.....	S107
12. Computational pharmacokinetic parameters.....	S109
13. Molecular Modelling	S117

1. Preparation of *N*-(*tert*-butoxycarbonyl)-*N'*-substituted thioureas¹

Thiourea (1.0 eq., 6.58 mmol, 501 mg) was dissolved in dry tetrahydrofuran (70 mL) under argon at 0 °C, to which 4.5 equivalents of sodium hydride (60% suspension in mineral oil, 4.5 eq., 29.61 mmol, 788 mg) was added. The reaction was stirred at RT for 45 min to complete formation of the anion and re-cooled to 0 °C prior to the addition of di-*tert*-butyl dicarbonate (2.2 eq., 14.48 mmol, 3.160 g). After stirring at RT for 8 h, the reaction was re-cooled to 0 °C and sodium hydride (60% suspension in mineral oil, 1.7 eq., 11.19 mmol, 298 mg) was added. After 1 h trifluoroacetic anhydride (1.54 eq., 10.13 mmol, 1.431 mL) was added and the reaction was stirred for 1 h before the appropriate amine (1.54 eq., 10.13 mmol) was added and the reaction was allowed to come to RT overnight. The reaction was then cooled to 0 °C and dropwise H₂O (20 mL) was added to quench the reaction. The product was extracted with EtOAc (3 × 20 mL) and the combined organic phases were washed with brine (sat. 30 mL) and H₂O (30 mL), dried over anhydrous MgSO₄, filtered and concentrated under vacuum. The resulting residue was purified by silica gel chromatography using gradient elution (hexane:EtOAc), followed by removal of solvents under vacuum to afford the product.

N-(*tert*-Butoxycarbonyl)-*N'*-(2-hydroxyethyl) thiourea

Thiourea (600 mg, 7.88 mmol) was dissolved in dry THF (60 mL) under argon at 0 °C and NaH (60% suspension in mineral oil, 4.5 eq., 851 mg, 35.47 mmol) was added. After 45 min stirring at RT and re-cooling to 0 °C di-*tert*-butyl dicarbonate (2.2 eq., 3785 mg, 17.34 mmol) was added and stirring continued at RT for 8 h. The mixture was cooled to 0 °C and further NaH (60% suspension in mineral oil, 1.7 eq., 322 mg, 13.40 mmol) was added. After 1 h trifluoroacetic anhydride (1.54 eq., 1.72 mL, 12.14 mmol) was added and the reaction was stirred for 1 h before ethanolamine (1.54 eq., 733 µL, 12.14 mmol) was added and stirring was continued for 14 h. Usual workup and purification by trituration in cold hexane yielded product (855 mg, 43%) as a white powder. M.p. 100-102 °C, clean melt. δ_{H} (400 MHz, CDCl₃): 1.48 (s, 9H, Boc CH₃), 2.82 (broad s, 1H, OH), 3.82-3.88 (m, 4H, 2 CH₂), 8.36 (broad s, 1H, NH), 10.01 (broad s, 1H, NH). δ_{C} (100 MHz, CDCl₃): 28.0 (CH₃, Boc), 47.5 (CH₂), 60.7 (CH₂), 83.7 (q 'Bu, Boc), 151.9 (q CO, Boc), 180.3 (q). ν_{max} (ATR)/cm⁻¹: 3217

(NH), 2981, 2937, 2881, 1709 (C=O), 1559, 1526, 1449, 1388, 1373, 1364, 1327, 1251, 1148 (C=S), 1045, 1004. HRMS (*m/z* ESI⁺): Found: 243.0781 (M⁺ + Na. C₈H₁₆N₂O₃SNa Requires: 243.0779).

N-(tert-Butoxycarbonyl)-N'-phenyl thiourea

Thiourea (600 mg, 7.88 mmol) was dissolved in dry THF (60 mL) under argon at 0 °C and NaH (60% suspension in mineral oil, 4.5 eq., 851 mg, 35.47 mmol) was added. After 45 min stirring at RT and re-cooling to 0 °C di-*tert*-butyl dicarbonate (2.2 eq., 3785 mg, 17.34 mmol) was added and stirring continued at RT for 8 h. The mixture was cooled to 0 °C and further NaH (60% suspension in mineral oil, 1.7 eq., 322 mg, 13.40 mmol) was added. After 1 h trifluoroacetic anhydride (1.54 eq., 1.72 mL, 12.14 mmol) was added and the reaction was stirred for 1 h before aniline (1.54 eq., 1.11 mL, 12.14 mmol) was added and stirring was continued for 14 h. Usual workup and purification by silica gel chromatography eluting with hexane:EtOAc yielded product (1070 mg, 54%) as a white, crystalline solid. M.p. 105-107 °C, clean melt. δ_H (400 MHz, CDCl₃): 1.56 (s, 9H, Boc CH₃), 7.28 (t, 1H, J 7.7, Ar), 7.42 (t, 2H, J 7.7, Ar), 7.67 (d, 1H, J 7.7, Ar), 8.10 (broad s, 1H, NH), 11.54 (broad s, 1H, NH). δ_C (100 MHz, CDCl₃): 28.0 (CH₃, Boc), 84.3 (q ¹Bu, Boc), 124.3 (CH Ar), 126.7 (CH Ar), 128.8 (CH Ar), 137.7 (q Ar), 151.9 (q CO, Boc), 178.3 (q). ν_{max} (ATR)/cm⁻¹: 3172 (NH), 3006 (NH), 2984, 1709 (C=O), 1591, 1528, 1477, 1451, 1391, 1366, 1321, 1252, 1196, 1143, 1075, 1048, 1016, 1004. HRMS (*m/z* ESI⁺): Found: 275.0828 (M⁺ + Na. C₁₂H₁₆N₂O₂SNa Requires: 275.0830).

N-(tert-Butoxycarbonyl)-N'-(2-furanylmethyl) thiourea

Thiourea (400 mg, 5.25 mmol) was dissolved in dry THF (40 mL) under argon at 0 °C and NaH (60% suspension in mineral oil, 4.5 eq., 567 mg, 23.65 mmol) was added. After 45 min stirring at RT and re-cooling to 0 °C di-*tert*-butyl dicarbonate (2.2 eq., 2523 mg, 11.56 mmol) was added and stirring continued at RT for 8 h. The mixture was cooled to 0 °C and further NaH (60% suspension in mineral oil, 1.7 eq., 215 mg, 8.93 mmol) was added. After 1 h trifluoroacetic anhydride (1.54 eq., 1.15 mL, 8.09 mmol) was added and the reaction was stirred for 1 h before furfurylamine (1.54 eq., 715 μ L, 8.09 mmol) was added and stirring was continued for 14 h. Usual workup and purification by trituration in cold hexane yielded

product (764 mg, 58%) as a white powder. M.p. 99-100 °C, clean melt. δ_{H} (400 MHz, CDCl_3): 1.51 (s, 9H, Boc CH_3), 4.88 (m, 2H, CH_2), 6.37 (d, 2H, J 2.9, Ar), 7.43 (s, 1H, Ar), 7.94 (broad t, 1H, J 5.4, NH), 9.66 (broad s, 1H, NH). δ_{C} (100 MHz, CDCl_3): 27.5 (CH_3 , Boc), 42.0 (CH_2), 83.4 (q ^tBu , Boc), 108.1 (CH Ar), 110.0 (CH Ar), 142.2 (CH Ar), 149.0 (q CO, Boc), 151.2 (q Ar), 179.1 (q). ν_{max} (ATR)/ cm^{-1} : 3279, 3251 (NH), 3174 (NH), 2983, 1711 (C=O), 1642, 1535, 1443, 1368, 1321, 1252, 1132 (C=S), 1011. HRMS (m/z ESI $^+$): Found: 279.0793 ($\text{M}^+ + \text{Na}$. $\text{C}_{11}\text{H}_{16}\text{N}_2\text{O}_3\text{SNa}$ Requires: 279.0779).

N-(tert-Butoxycarbonyl)-N'-propyl thiourea

Thiourea (600 mg, 7.88 mmol) was dissolved in dry THF (60 mL) under argon at 0 °C and NaH (60% suspension in mineral oil, 4.5 eq., 851 mg, 35.47 mmol) was added. After 45 min stirring at RT and re-cooling to 0 °C di-*tert*-butyl dicarbonate (2.2 eq., 3785 mg, 17.34 mmol) was added and stirring continued at RT for 8 h. The mixture was cooled to 0 °C and further NaH (60% suspension in mineral oil, 1.7 eq., 322 mg, 13.40 mmol) was added. After 1 h trifluoroacetic anhydride (1.54 eq., 1.72 mL, 12.14 mmol) was added and the reaction was stirred for 1 h before *n*-propylamine (1.54 eq., 1.00 mL, 12.14 mmol) was added and stirring was continued for 14 h. Usual workup and purification by silica gel chromatography eluting with hexane:EtOAc yielded product (1218 mg, 71%) as a white, crystalline solid. M.p. 58-60 °C, clean melt. δ_{H} (400 MHz, CDCl_3): 1.01 (t, 3H, J 7.3, CH_3), 1.52 (s, 9H, Boc CH_3), 1.71 (app. q, 2H, J 7.3, CH_2), 3.63 (m, 2H, CH_2), 7.97 (broad s, 1H, NH), 9.74 (broad s, 1H, NH). δ_{C} (100 MHz, CDCl_3): 11.3 (CH_3), 21.5 (CH_2), 27.8 (CH_3 , Boc), 47.1 (CH_2), 83.4 (q ^tBu , Boc), 151.8 (q CO, Boc), 179.4 (q2). ν_{max} (ATR)/ cm^{-1} : 3245 (NH), 3175 (NH), 2961, 2934, 2875, 1720 (C=O), 1523, 1243, 1206, 1142 (C=S), 1073, 1008. HRMS (m/z ESI $^+$): Found: 219.1167 ($\text{M}^+ + \text{H}$. $\text{C}_{9}\text{H}_{19}\text{N}_2\text{O}_2\text{S}$ Requires: 219.1167).

N-(tert-Butoxycarbonyl)-N'-(2-acetoxyethyl) thiourea

Over a solution of *N-(tert-Butoxycarbonyl)-N'-(2-hydroxyethyl) thiourea* (600 mg, 2.73 mmol) in CH_2Cl_2 (6 mL) at 0 °C were added pyridine (3.0 eq., 658 μL , 8.18 mmol), acetic anhydride (1.5 eq., 386 μL , 4.09 mmol) and 4-(dimethylamino)pyridine (0.05 eq., 17 mg, 0.14 mmol). The mixture was stirred at RT for 3 h, after which NaHCO_3 (saturated, 15 mL) was added to quench the reaction. The mixture was stirred for 30 min and then extracted with

Et_2O (3×20 mL). The combined organic layers were washed with 0.5 M HCl (15 mL), brine (15 mL) and water (15 mL). The organic extract was dried over MgSO_4 , filtered and concentrated under vacuum to yield product (650 mg, 91%) as a white, crystalline solid. M.p. 95-97 °C, clean melt. δ_{H} (400 MHz, CDCl_3): 1.48 (s, 9H, Boc CH_3), 2.08 (s, 3H, CH_3), 3.93 (q, 2H, J 5.1, CH_2), 4.27 (t, 2H, J 5.1, CH_2), 8.39 (broad s, 1H, NH), 9.93 (broad s, 1H, NH). δ_{C} (100 MHz, CDCl_3): 20.4 (CH_3), 27.5 (CH_3 , Boc), 43.9 (CH_2), 61.6 (CH_2), 83.5 (q ^1Bu , Boc), 151.3 (q CO, Boc), 170.4 (q CO, Ac), 179.8 (q). ν_{max} (ATR)/cm⁻¹: 3259 (NH), 3179 (NH), 2988, 2957, 1738, 1718 (C=O), 1558, 1526, 1391, 1365, 1329, 1240, 1195, 1133, 1050, 1039. HRMS (*m/z* ESI⁺): Found: 285.0876 ($\text{M}^+ + \text{Na}$. $\text{C}_{10}\text{H}_{18}\text{N}_2\text{O}_4\text{SNa}$ Requires: 285.0885).

2. Preparation of *S*-methyl-*N*-substituted dithiocarbamates

To a solution of carbon disulphide (1.1 eq., 3.72 mmol, 225 μL) and triethylamine (1.1 eq., 3.72 mmol, 519 μL) in CH_2Cl_2 (4 mL) at 0 °C was added starting amine (1.0 eq., 3.38 mmol). After 15 min methyl iodide (1.1 eq., 3.72 mmol, 232 μL) was added dropwise. The reaction was warmed to RT and stirred for 2 h. It was then diluted with EtOAc (30 mL) and added to a 1 M solution of H_2SO_4 (30 mL). The aqueous layer was extracted with EtOAc (2 \times 30 mL) and the combined organic layers were washed with water (2 \times 20 mL) and dried over MgSO_4 . Filtration and removal of solvents yielded a residue which was purified either by recrystallisation from hexane or silica gel column chromatography, eluting with hexane:EtOAc, as appropriate.

S-Methyl-*N*-(2-hydroxyethyl) dithiocarbamate

Ehanolamine (1.0 eq., 198 μL , 3.27 mmol) was added to a solution of carbon disulphide (1.1 eq., 217 μL , 3.60 mmol) and triethylamine (1.1 eq., 502 μL , 3.60 mmol) in CH_2Cl_2 (3 mL) at 0 °C. After 15 min methyl iodide (1.1 eq., 224 μL , 3.60 mmol) was added dropwise and the reaction was stirred at RT for 2 h. Usual workup, followed by silica gel chromatography, eluting with hexane:EtOAc yielded product (339 mg, 68%) as a colourless oil. The product, **54a**, was obtained as a mixture of isomers (7:2). δ_{H} (400 MHz, CDCl_3): *Major isomer*; 2.59 (s, 3H, CH_3), 3.77-3.91 (m, 4H, 2 CH_2), 8.18 (broad s, 1H, NH). δ_{H} (400 MHz, CDCl_3): *Minor isomer*; 2.64 (s, 3H, CH_3), 3.54-3.61 (m, 2H, CH_2), 3.77-3.91 (m, 2H, CH_2), 8.73

(broad s, 1H, NH). δ_{C} (100 MHz, CDCl_3): *Major isomer*; 17.8 (CH₃), 48.8 (CH₂), 59.9 (CH₂), 199.5 (q). δ_{C} (100 MHz, CDCl_3): *Minor isomer*; 18.5 (CH₃), 21.0 (CH₃), 48.0 (CH₂), 59.4 (CH₂), 201.8 (q). ν_{max} (ATR)/cm⁻¹: 3227 (NH), 3009 (NH), 2919, 2880, 1504, 1423, 1382, 1326, 1305, 1266, 1213, 1108 (C=S), 1051, 1003, 870, 789. HRMS (*m/z* ESI): Found: 150.0052 (M⁻ - H. $\text{C}_4\text{H}_8\text{NOS}_2$ Requires: 150.0047).

***S*-Methyl-*N*-phenyl dithiocarbamate**

Aniline (1.0 eq., 587 μL , 6.44 mmol) was added to a solution of carbon disulphide (1.1 eq., 428 μL , 7.09 mmol) and triethylamine (1.1 eq., 988 μL , 7.09 mmol) in CH_2Cl_2 (6 mL) at 0 °C. After 15 min methyl iodide (1.1 eq., 441 μL , 7.09 mmol) was added dropwise and the reaction was stirred at RT for 2 h. Usual workup, followed by trituration in cold hexane yielded product (803 mg, 68%) as a white, crystalline solid. M.p. 90-92 °C, clean melt, lit. 92-93 °C.² δ_{H} (400 MHz, CDCl_3): 2.68 (s, 3H, CH₃), 7.35 (t, 1H, J 7.0), 7.42-7.49 (m, 4H, Ar), 9.03 (broad s, 1H, NH).

***S*-Methyl-*N*-(2-furanylmethyl) dithiocarbamate**

Furfurylamine (1.0 eq., 546 μL , 6.18 mmol) was added to a solution of carbon disulphide (1.1 eq., 410 μL , 6.80 mmol) and triethylamine (1.1 eq., 948 μL , 6.80 mmol) in CH_2Cl_2 (6 mL) at 0 °C. After 15 min methyl iodide (1.1 eq., 423 μL , 6.80 mmol) was added dropwise and the reaction was stirred at RT for 2 h. Usual workup, followed by silica gel chromatography, eluting with hexane:EtOAc, yielded product (926 mg, 80%) as an off-white solid. M.p. 47-48 °C, clean melt. δ_{H} (400 MHz, CDCl_3): 2.61 (s, 3H, CH₃), 4.89 (d, 2H, J 4.9, CH₂), 6.32-6.35 (m, 2H, Ar), 7.37 (s, 1H, Ar), 7.45 (broad s, 1H, NH). δ_{C} (100 MHz, CDCl_3): 18.3 (CH₃), 43.8 (CH₂), 109.0 (CH Ar), 110.7 (CH Ar), 142.7 (CH Ar), 149.3 (q Ar), 199.2 (q). ν_{max} (ATR)/cm⁻¹: 3221 (NH), 2996, 2919, 1641, 1591, 1493, 1422, 1367, 1321, 1304, 1269, 1190, 1146 (C=S), 1086, 1063, 1010, 927, 883, 864, 843, 816, 738, 694. HRMS (*m/z* ESI): Found: 186.0041 (M⁻ - H. $\text{C}_7\text{H}_8\text{NOS}_2$ Requires: 186.0047).

***S*-Methyl-*N*-propyl dithiocarbamate**

n-Propylamine (1.0 eq., 278 μ L, 3.38 mmol) was added to a solution of carbon disulphide (1.1 eq., 225 μ L, 3.72 mmol) and triethylamine (1.1 eq., 519 μ L, 3.72 mmol) in CH_2Cl_2 (4 mL) at 0 °C. After 15 min methyl iodide (1.1 eq., 232 μ L, 3.72 mmol) was added dropwise and the reaction was stirred at RT for 2 h. Usual workup, followed by silica gel chromatography, eluting with hexane:EtOAc, yielded product (450 mg, 89%) as a colourless oil. The product was obtained as a mixture of isomers. δ_{H} (400 MHz, CDCl_3): *Major isomer*; 0.91-0.97 (m, 3H, CH_3), 1.61-1.72 (m, 2H, CH_2), 2.59 (s, 3H, CH_3), 3.63-3.68 (m, 2H, CH_2), 7.31 (broad s, 1H, NH). δ_{H} (400 MHz, CDCl_3): *Minor isomer*; 0.95-1.01 (m, 3H, CH_3), 1.61-1.72 (m, 2H, CH_2), 2.63 (s, 3H, CH_3), 3.37 (t, 2H, J 7.1, CH_2), 8.21 (broad s, 1H, NH). δ_{C} (100 MHz, CDCl_3): *Major isomer*; 11.4 (CH_3), 18.1 (CH_3), 21.7 (CH_2), 49.0 (CH_2), 198.7 (q). δ_{C} (100 MHz, CDCl_3): *Minor isomer*; 11.3 (CH_3), 18.8 (CH_3), 22.0 (CH_2), 48.2 (CH_2), 201.5 (q). ν_{max} (ATR)/cm⁻¹: 3222 (NH), 2962, 2931, 2874, 1502, 1459, 1425, 1389, 1345, 1305, 1291, 1249, 1153 (C=S), 1062, 1002, 936, 883, 856, 771, 749, 727. HRMS (*m/z* ESI): Found: 148.0259 ($\text{M}^- - \text{H}$. $\text{C}_5\text{H}_{10}\text{NS}_2$ Requires: 148.0255).

S-Methyl-*N*-(2-acetoxyethyl) dithiocarbamate 2

Methyl (2-hydroxyethyl)carbamodithioate (1.0 eq., 1300 mg, 8.60 mmol), triethylamine (3.0 eq., 3.59 mL, 25.79 mmol) and acetic anhydride (1.1 eq., 892 μ L, 9.46 mmol) were added to CH_2Cl_2 (21 mL) under stirring at 0 °C. The reaction was warmed to RT and stirred for 2 h. At this point TLC showed no starting material and the reaction was diluted with CH_2Cl_2 (30 mL). The organic layer was separated, washed with brine (30 mL) and water (2 \times 30 mL), dried over MgSO_4 and filtered. Removal of solvents under reduced pressure yielded a residue which was purified using silica-gel chromatography (hexane:EtOAc), affording product (1609 mg, 97%) obtained as a colourless oil, in a mixture of isomers (85:15). δ_{H} (400 MHz, CDCl_3): *Major isomer*; 2.06 (s, 3H, CH_3), 2.59 (s, 3H, CH_3), 3.95-4.00 (m, 2H, CH_2), 4.27-4.33 (m, 2H, CH_2), 7.73 (broad s, 1H, NH). δ_{H} (400 MHz, CDCl_3): *Minor isomer*; 2.06 (s, 3H, CH_3), 2.60 (s, 3H, CH_3), 3.95-4.00 (m, 2H, CH_2), 4.27-4.33 (m, 2H, CH_2), 8.12 (broad s, 1H, NH). δ_{C} (100 MHz, CDCl_3): *Major isomer*; 18.1 (CH_3), 20.9 (CH_3), 46.2 (CH_2), 62.1 (CH_2), 171.3 (q, CO), 199.8 (q). δ_{C} (100 MHz, CDCl_3): *Minor isomer*; 18.1 (CH_3), 21.0 (CH_3), 45.0 (CH_2), 61.7 (CH_2), 171.7 (q, CO), 202.3 (q). ν_{max} (ATR)/cm⁻¹: 3292 (NH), 2919, 1720 (C=O), 1508 (C=S), 1427, 1378, 1332, 1308, 1222, 1132, 1044, 950, 881, 808, 727. HRMS (*m/z* ESI): Found: 192.0146 ($\text{M}^- - \text{H}$. $\text{C}_6\text{H}_{10}\text{NO}_2\text{S}_2$ Requires: 192.0153).

S-Methyl-N-(benzo[d][1,3]dioxol-5-ylmethyl) dithiocarbamate

Benzo[d][1,3]dioxol-5-ylmethanamine (1.0 eq., 934 mg, 6.18 mmol) was added to a solution of carbon disulphide (1.1 eq., 410 μ L, 6.80 mmol) and triethylamine (1.1 eq., 948 μ L, 6.80 mmol) in CH_2Cl_2 (6 mL) at 0 °C. After 15 min methyl iodide (1.1 eq., 423 μ L, 6.80 mmol) was added dropwise and the reaction was stirred at RT for 2 h. Usual workup, followed by silica gel chromatography, eluting with hexane:EtOAc, yielded product (761 mg, 51%) as a yellow solid. M.p. 96 °C, clean melt. δ_{H} (400 MHz, CDCl_3): 2.55 (s, 3H, CH_3), 4.73 (d, 2H, J 4.0, CH_2), 5.85 (s, 2H, CH_2 , -OCH₂O-), 6.68-6.70 (m, 3H, Ar), 7.65 (broad s, 1H, NH). δ_{C} (100 MHz, CDCl_3): 18.1 (CH_3), 50.8 (CH_2), 101.1 (CH_2 , -OCH₂O-), 106.3 (CH Ar), 108.7 (CH Ar), 121.7 (CH Ar), 130.2 (q Ar), 147.4 (q Ar), 147.8 (q Ar), 198.9 (q, C=S). ν_{max} (ATR)/cm⁻¹: 3180 (NH), 2995, 2959, 2902, 1651, 1520, 1497, 1482, 1424, 1376, 1346, 1310, 1272, 1240, 1191, 1132 (C=S), 1101, 960, 935, 908, 856, 768, 729, 698. HRMS (*m/z* ESI): Found: 240.0153 (M⁺ - H. $\text{C}_{10}\text{H}_{10}\text{NO}_2\text{S}_2$ Requires: 240.0148).

3. Preparation of non-commercial starting amines

2-amino-5,6,7,8-tetrahydroquinoline

This compound was prepared according to the procedure of Vijn *et al.*³

3-amino-5,6,7,8-tetrahydroquinoline

This compound was prepared according to the procedure of Tohda *et al.*⁴

2-(*N*-Ethylamino)-5-aminopyridine

N-(*Pyridin-2-yl)acetamide*

To a solution of 2-aminopyridine (1.0 eq., 500 mg, 5.31 mmol) in CH_2Cl_2 at RT were added triethylamine (3.0 eq., 2.22 mL, 15.94 mmol) and acetic anhydride (2.0 eq., 1.00 mL, 10.63 mmol). Stirring was continued for 6 h, after which the mixture was diluted with EtOAc (30 mL). The organic layer was washed with H₂O (2 \times 15 mL), dried over MgSO₄, filtered, and concentrated under vacuum to yield a colourless oil which was purified by silica gel chromatography, eluting with hexane:EtOAc. Removal of solvent yielded product (650 mg, 90%) as a yellow/white solid. M.p. 75-76 °C, clean melt, lit., 70- 71 °C. δ_{H} (400 MHz, CDCl_3): 2.14

(s, 3H, CH₃), 6.96-6.99 (m, 1H, Ar), 7.63-7.66 (m, 1H, Ar), 8.18-8.21 (m, 2H, Ar), 9.84 (broad s, 1H, NH).

2-(N-Ethylamino)pyridine

To a solution of 33 (1.0 eq., 400 mg, 2.94 mmol) in dry tetrahydrofuran (30 mL) at 0 °C was added lithium aluminium hydride (5.0 eq., 557 mg, 14.69 mmol). The mixture was stirred at RT for 16 h, after which H₂O (30 mL) was added to quench the reaction. The mixture was filtered through celite and the organic phase was extracted with EtOAc (3 × 30 mL), washed with H₂O (2 × 15 mL), dried over MgSO₄, filtered, and concentrated under reduced pressure to yield product (266 mg, 74%) as a red liquid. δ_{H} (400 MHz, CDCl₃): 1.24 (t, 3H, J 7.2, CH₃), 3.28 (q, 2H, J 7.2, CH₂), 4.65 (broad s, 1H, NH), 6.37 (d, 1H, J 8.4, Ar), 6.54 (m, 1H, Ar), 7.41 (app. dt, 1H, J 8.4, 1.9, Ar), 8.06 (dd, 1H, J 5.0, 1.9, Ar). δ_{C} (100 MHz, CDCl₃): 14.8 (CH₃), 36.9 (CH₂), 106.3 (CH Ar), 112.6 (CH Ar), 137.5 (CH Ar), 148.1 (CH Ar), 158.9 (q Ar). ν_{max} (ATR)/cm⁻¹: 2959 (NH), 1610, 1571, 1482, 1443, 1320, 1273, 1253, 1150, 1046, 989, 846, 631, 550, 519. HRMS (*m/z* ESI⁺): Found: 123.0921 (M⁺ + H. C₇H₁₁N₂ Requires: 123.0922).

2-(N-Ethylamino)-5-nitropyridine

Aqueous sulfuric acid (20%, 2.5 eq., 5.10 mL, 5.10 mmol) and potassium nitrate (1.1 eq., 228 mg, 2.25 mmol) were added to 2-(N-Ethylamino)pyridine (1.0 eq., 250 mg, 2.05 mmol) and the mixture was stirred at RT for 5 h. The reaction was cooled to 0 °C and aqueous ammonia was added dropwise until a pH of 12 was reached. The resulting precipitate was extracted with EtOAc (3 × 30 mL), washed with brine (20 mL) and water (2 × 20 mL), dried over anhydrous MgSO₄, filtered and concentrated under reduced pressure to yield a yellow/brown solid which was purified by silica gel column chromatography, eluting with 1:1 hexane:EtOAc. Removal of solvent yielded product (171 mg, 50%) as a yellow solid. M.p. 115-116 °C, lit., 117-119 °C. δ_{H} (400 MHz, CDCl₃): 1.26 (t, 3H, J 7.0, CH₃), 3.40 (broad s, 2H, CH₂), 6.13 (broad s, 1H, NH), 6.35 (d, 1H, J 9.3, Ar), 8.10 (broad s, 1H, Ar), 8.93 (s, 1H, Ar).

2-(N-Ethylamino)-5-aminopyridine

To a solution of 2-(N-Ethylamino)-5-nitropyridine (1.0 eq., 200 mg, 1.20 mmol) in EtOAc (12 mL) was added 10% Pd/C (25 mg, 0.02 mmol, 2 mol%). The mixture was stirred under a hydrogen atmosphere (3 atm.) for 5 h. It was then filtered through filter paper and concentrated under reduced pressure to yield product (157 mg, 95%) as a dark red solid. M.p. 96-97 °C, clean melt, lit. 95-98 °C. δ_{H} (400 MHz, DMSO-D₆): 1.08 (t, 3H, J 8.0, CH₃),

3.10 (m, 2H, CH₂), 4.26 (broad s, 2H, NH₂), 5.44 (broad s, 1H, NH), 6.26 (d, 1H, J 8.0, Ar), 6.81 (dd, 1H, J 8.0, 1.9, Ar), 7.45 (s, 1H, Ar).

2-Amino-5-ethylaminopyridine

To a solution of 2,5-diaminopyridine (250 mg, 2.29 mmol) in ethanol (11 mL) was added ethyl mesylate (1.00 eq., 236 μ L, 2.29 mmol). The mixture was stirred at 60 °C for 16 h. The product was extracted with a 20% solution of iPrOH/CH₂Cl₂ (3 \times 20 mL), washed with saturated NaHCO₃ (2 \times 20 mL), dried over anhydrous MgSO₄, filtered and concentrated under reduced pressure to yield a residue that was purified by silica gel column chromatography, eluting with 4:1 CH₂Cl₂/CH₃OH. Removal of solvent afforded product (149 mg, 47%) as a red liquid. The position of alkylation was confirmed by a NOE signal from H₃ to the NH₂. δ _H (400 MHz, CDCl₃): 1.11 (t, 3H, J 6.9, CH₃), 2.92 (q, 2H, J 6.9, CH₂), 4.66 (broad s, 1H, NH, NHEt), 5.00 (broad s, 2H, NH₂), 6.34 (d, 1H, J 8.9, Ar), 6.82 (dd, 1H, 8.9, 3.0, Ar), 7.36 (d, 1H, J 3.0, Ar). δ _C (100 MHz, CDCl₃): 14.6 (CH₃), 38.9 (CH₂), 108.8 (CH Ar), 124.1 (CH Ar), 131.5 (CH Ar), 137.1 (q Ar), 151.8 (q Ar). ν _{max} (ATR)/cm⁻¹: 3314 (NH), 2968, 2871, 1625, 1578, 1496, 1392, 1279, 1240, 1144, 1100, 1059, 1015, 820. HRMS (*m/z* ESI⁺): Found: 138.1027 (M⁺ + H, C₇H₁₂N₃ Requires: 138.1031).

2-Amino-3aminomethylpyridine

To a solution of 2-aminopyridine-3-carbonitrile (300mg, 2.52mmol), in 7N NH₃/CH₃OH (5ml), was added 10% Pd/C (50mg). The mixture was stirred under an atmosphere of hydrogen (3 atm.) for 12 h. The resulting solution was diluted with CH₃OH (40ml), filtered through celite, and concentrated under reduced pressure, to yield product (284 mg, 90%) as a white solid. 121 °C, clean melt. δ _H (400 MHz, CDCl₃): 1.92 (s, 2H, NH₂CH₂), 3.95 (s, 2H, CH₂), 5.21 (s, 2H, NH₂), 6.53 (m, 1H, Ar), 7.31 (d, 1H, J 4.0, Ar), 7.89 (s, 1H, Ar). δ _C (100 MHz, CDCl₃): 42.0 (CH₂), 112.9 (CH Ar), 114 (q Ar), 133.1 (CH Ar), 146.4 (CH Ar), 154.5 (q Ar). ν _{max} (ATR)/cm⁻¹: 3349 (NH), 3282 (NH), 3011, 2862, 2636, 1627, 1600, 1574, 1439, 1381, 1323, 1289, 1274, 1239, 1132, 1071, 1024, 975, 928, 815, 771, 760, 754, 697. HRMS (*m/z* ESI⁺): Found: 124.0875 (M⁺ + H, C₆H₁₀N₃ Requires: 124.0875). δ _C (100 MHz, CDCl₃): 14.2 (CH₃), 36.9 (CH₂), 132.6 (CH Ar), 146.8 (CH Ar), 161.1 (q Ar), 135.1 (CH Ar), 105.3 (q Ar). ν _{max} (ATR)/cm⁻¹: 3343 (NH), 2980, 2934, 1601, 1550 (NO₂), 1469, 1465, 1408, 1367, 1321, 1279, 1248, 1163, 1133, 1109, 1100, 1060, 994, 973, 951, 861, 824, 766, 730. HRMS (*m/z* ESI⁺): Found: 168.0772 (M⁺ + H, C₇H₁₀N₃O₂ Requires: 168.0773).

4. Synthesis and Characterisation of Boc-protected/neutral guanidine intermediates

Preparation of 1-(pyridinyl)-2,3-di(*tert*-butoxycarbonyl)guanidines, 1-(pyridinyl)-2,3-di(*tert*-butoxycarbonyl)-2-iminoimidazolidines, 1-(pyridinyl)-2-(*tert*-butoxycarbonyl)-3-substituted guanidines – Procedure A.

To a solution of starting amine (1.00 eq., 1.06 mmol), the appropriate thiourea derivative – *N,N'*-bis(*tert*-butoxycarbonyl)-*S*-methylisothiourea, *N,N'*-di(*tert*-butoxycarbonyl)imidazolidine-2-thione⁵ or *N*-(*tert*-butoxycarbonyl)-*N'*-substituted thiourea – (1.05 eq., 1.11 mmol) and triethylamine (3.5 eq., 3.71 mmol, 517 µL) in CH₂Cl₂ (5.5 mL) at 0 °C was added mercury(II) chloride (1.05 eq., 1.11 mmol, 301 mg). The mixture was stirred for 30 min at 0 °C, then warmed to RT and stirred until reaction was complete, as adjudged by disappearance of starting material in TLC analysis. The reaction mixture was diluted with EtOAc (50 mL) and filtered through a pad of Celite to remove any mercury by-products. The filtrate was washed with brine (20 mL) and water (20 mL), dried over anhydrous MgSO₄, filtered and concentrated under reduced pressure to yield a residue that was purified by silica gel column chromatography, eluting with the appropriate hexane:EtOAc mixture. Where necessary, recrystallisation was carried out as described below for specific compounds.

Preparation of *N*-substituted- 1,4-dihydroquinazolin-2-amines and 1,4-dihydropyridopyrimidin-2-amines – Procedure C⁶

To a suspension of 2-aminobenzylamine (1.0 eq., 1.19 mmol, 145 mg) and the appropriate *S*-methyl-*N*-substituted dithiocarbamate (1.1 eq., 1.31 mmol) in dimethylformamide (4 mL) at RT were added Cu(II)O (0.2 eq., 0.24 mmol, 19 mg) and K₂CO₃ (2.0 eq., 2.37 mmol, 328 mg). The resulting mixture was heated to 60 °C and kept at this temperature for 2 h. It was then cooled to RT, diluted with EtOAc (60 mL) and filtered through Celite. The filtrate was washed with brine (30 mL) and water (4 × 30 mL) to remove traces of dimethylformamide, dried over MgSO₄, filtered and concentrated under vacuum. The resulting residue was purified using silica gel column chromatography, eluting with the appropriate hexane:EtOAc mixture.

1-(Pyridin-2-yl)-2,3-di(*tert*-butoxycarbonyl)guanidine (5a) – Procedure A with *N,N'*-bis(*tert*-butoxycarbonyl)-*S*-methylisothiourea. Colourless crystals (79%) after recrystallisation from hexane:EtOAc. Mp. 138-140 °C, clean melt. δ_H (600 MHz, CDCl₃): 1.53 (s, 18H, CH₃, Boc), 7.01 (app. t, 1H, J 5.4, Ar), 7.70 (app. t, 1H, J 7.3, Ar), 8.29 (d, 1H, J 4.0, Ar), 8.37

(broad s, 1H, Ar), 10.89 (broad s, 1H, NH), 11.53 (broad s, 1H, NH). δ_{C} (150 MHz, CDCl_3): 28.0 (CH_3 , Boc), 28.1 (CH_3 , Boc), 79.9 (q, ^tBu , Boc), 83.9 (q, ^tBu , Boc), 116.0 (CH Ar), 119.7 (CH Ar), 138.1 (CH Ar), 148.0 (CH Ar), 150.6 (q, Ar), 152.6 (q, CO, Boc), 153.1 (q, Gua), 163.2 (q, CO, Boc). ν_{max} (ATR)/ cm^{-1} : 3253 (NH), 2979, 1725 (C=O), 1621 (C=N), 1586, 1570, 1479, 1398, 1368, 1332, 1302, 1293, 1256, 1229, 1147, 1121, 1089, 1030, 994, 883, 848, 809, 763, 733, 710, 669. HRMS (ESI $^+$) m/z : [M + H] $^+$ Calcd. for $\text{C}_{16}\text{H}_{25}\text{N}_4\text{O}_4$ 337.1876; Found: 337.1882.

1-(Pyridin-2'-yl)-2,3-di(*tert*-butoxycarbonyl)-2-iminoimidazolidine (5b) – Procedure A with *N,N'*-di(*tert*-butoxycarbonyl) imidazolidine-2-thione. Colourless crystals (56%). Mp. 140 °C, clean melt. δ_{H} (400 MHz, CDCl_3): 1.47 (s, 18H, CH_3 , Boc), 3.71 (s, 4H, CH_2), 6.81 (ddd, 1H, J 7.3, 5.0, 1.0, Ar), 7.54 (app. td, 1H, J 7.3, 2.0, Ar), 7.99 (broad s, 1H, Ar), 8.17 (dd, 1H, J 2.0, 5.0, Ar). δ_{C} (100 MHz, CDCl_3): 28.2 (CH_3 , Boc), 45.1 (2 CH_2), 82.6 (q, ^tBu , Boc), 113.1 (CH Ar), 117.6 (CH Ar), 137.7 (CH Ar), 147.7 (CH Ar), 149.8 (q, Ar), 150.3 (q, CO, Boc), 152.3 (q, Imi). ν_{max} (ATR)/ cm^{-1} : 3266, 2981, 2934, 2884, 1805, 1696 (C=O), 1649 (C=N), 1576, 1545, 1479, 1462, 1437, 1376, 1365, 1329, 1306, 1254, 1232, 1151, 1117, 1088, 852, 841, 769, 760, 748, 677. HRMS (ESI $^+$) m/z : [M + H] $^+$ Calcd. for $\text{C}_{18}\text{H}_{27}\text{N}_4\text{O}_4$ 363.2032; Found: 363.2026.

1-(Pyridin-2-yl)-2-(*tert*-butoxycarbonyl)-3-(phenyl)guanidine (5e) – Procedure A with *N*-(*tert*-Butoxycarbonyl)-*N'*-phenyl thiourea. Colourless oil (63%) identified as a mixture of isomers. δ_{H} (400 MHz, CDCl_3): 1.52 (s, 9H, CH_3 , Boc), 6.93 (d, 1H, J 8.2, Ar), 7.03 (m, 1H, Ar), 7.11 (m, 1H, Ar), 7.36 (m, 2H, Ar), 7.67 (d, 2H, J 8.0, Ar), 7.72 (m, 1H, Ar), 8.27 (s, 1H, Ar), 12.27 (broad s, 1H, NH), 12.63 (broad s, 1H, NH). δ_{C} (100 MHz, CDCl_3): 28.3 (CH_3 , Boc), 79.3 (q, ^tBu , Boc), 113.7 (CH Ar), 118.4 (CH Ar), 122.4 (CH Ar), 124.3 (CH Ar), 129.1 (CH Ar), 138.3 (q, Ar), 139.1 (CH Ar), 145.9 (CH Ar), 152.4 (q, CN), 155.2 (q, Ar), 164.4 (q, CO, Boc). ν_{max} (ATR)/ cm^{-1} : 2979, 1711 (C=O), 1646 (C=N), 1587, 1561, 1498, 1448, 1417, 1357, 1292, 1245, 1157, 1097, 1010, 809, 690, 752. HRMS (ESI $^+$) m/z : [M + Na] $^+$ Calcd. for $\text{C}_{17}\text{H}_{20}\text{N}_4\text{O}_2\text{Na}$ 335.1484; Found: 335.1494.

1-(Pyridin-2-yl)-2-(*tert*-butoxycarbonyl)-3-(2-acetoxyethyl)guanidine (5f) – Procedure A with *N*-(*tert*-Butoxycarbonyl)-*N'*-(2-acetoxyethyl) thiourea. Colourless oil (43%) identified as a mixture of isomers. δ_{H} (400 MHz, CDCl_3): 1.53 (s, 9H, CH_3 , Boc), 2.10 (s, 3H, CH_3), 3.80 (t, 2H, J 5.4, CH_2), 4.26 (t, 2H, J 5.4, CH_2), 6.84 (d, 1H, J 8.3, Ar), 6.95 (dd, 1H, J 6.9, 5.5, Ar), 7.64 (app. td, 1H, J 7.8, 1.6, Ar), 8.18 (d, 1H, J 5.2, Ar), 10.46 (broad s, 1H, NH), 12.09

(broad s, 1H, NH). δ_{C} (100 MHz, CDCl_3): 20.8 (CH_3), 28.4 (CH_3 , Boc), 39.6 (CH_2), 63.2 (CH_2), 78.8 (q ^tBu , Boc), 113.3 (CH Ar), 117.8 (CH Ar), 138.5 (CH Ar), 145.8 (CH Ar), 152.9 (q Ar), 157.7 (q, CN), 164.1 (q CO, Boc), 170.8 (q CO). ν_{max} (ATR)/cm⁻¹: 2979, 1742 (C=O), 1642 (C=N), 1590, 1559, 1453, 1353, 1311, 1234, 1140, 1046. HRMS (ESI⁺) m/z : [M + Na]⁺ Calcd. for $\text{C}_{15}\text{H}_{22}\text{N}_4\text{O}_4\text{Na}$ 345.1539; Found: 345.1537.

1-(Pyridin-2-yl)-2-(*tert*-butoxycarbonyl)-3-(2-furanylmethyl)guanidine (5g) – Procedure A with *N*-(*tert*-Butoxycarbonyl)-*N'*-(2-furanylmethyl) thiourea. White solid (61%). M.p. 107-108 °C, clean melt. δ_{H} (400 MHz, CDCl_3): 1.57 (s, 9H, CH_3 , Boc), 4.77 (d, 1H, J 5.0, CH_2), 6.31 (d, 1H, J 3.1, Ar), 6.35-6.38 (m, 1H, Ar), 6.87 (d, 1H, J 8.3, Ar), 6.96 (dd, 1H, J 7.2, 5.2, Ar), 7.42 (dd, 1H, J 1.7, 0.7, Ar), 7.65 (app. td, 1H, J 7.7, 1.8, Ar), 8.20 (dd, 1H, J 5.2, 1.2, Ar), 10.59 (broad s, 1H, NH), 12.14 (broad s, 1H, NH). δ_{C} (100 MHz, CDCl_3): 28.0 (CH_3 , Boc), 37.7 (CH_2), 78.4 (q ^tBu , Boc), 106.7 (CH Ar), 109.9 (CH Ar), 112.8 (CH Ar), 117.3 (CH Ar), 138.0 (CH Ar), 141.7 (CH Ar), 145.6 (CH Ar), 151.0 (q Ar), 152.4 (q Ar), 156.9 (q, CN), 163.6 (q CO, Boc). ν_{max} (ATR)/cm⁻¹: 3062 (NH), 2976, 2926, 1646 (C=N), 1609 C=N), 1596, 1562, 1508, 1480, 1446, 1419, 1385, 1350, 1336, 1263, 1250, 1235, 1220, 1170, 1157, 1149, 1121, 1101, 1086, 1060, 1017, 998, 967, 918, 879, 850, 802, 765, 755, 740, 696. HRMS (ESI⁺) m/z : [M + H]⁺ Calcd. for $\text{C}_{16}\text{H}_{21}\text{N}_4\text{O}_3$ 317.1614; Found: 317.1622.

1-(5-Bromopyridin-2-yl)-2,3-di(*tert*-butoxycarbonyl)guanidine (6a) – Procedure A with *N,N'*-*bis*-(*tert*-butoxycarbonyl)-*S*-methylisothiourea. Colourless crystals (80%) after recrystallisation from hexane:EtOAc. Mp. 125-126 °C, clean melt. δ_{H} (400 MHz, CDCl_3): 1.47 (s, 9H, CH_3 , Boc), 1.49 (s, 9H, CH_3 , Boc), 7.75 (dd, 1H, J 8.3, 2.1, Ar), 8.28 (d, 1H, J 2.1, Ar), 8.31 (d, 1H, J 8.3, Ar), 10.86 (broad s, 1H, NH), 11.49 (broad s, 1H, NH). δ_{C} (100 MHz, CDCl_3): 27.8 (CH_3 , Boc), 27.9 (CH_3 , Boc), 79.9 (q ^tBu , Boc), 83.9 (q ^tBu , Boc), 114.7 (CH Ar), 117.2 (q Ar), 140.3 (CH Ar), 148.6 (CH Ar), 149.1 (q Ar), 152.5 (q CO, Boc), 152.7 (q, Gua), 162.8 (q CO, Boc). ν_{max} (ATR)/cm⁻¹: 3247 (NH), 2980, 1715 (C=O), 1632 (C=N), 1593, 1553, 1453, 1404, 1367, 1324, 1287, 1252, 1232, 1148, 1129, 1101, 1057, 1028, 1004, 878, 841, 793, 745. HRMS (ESI⁺) m/z : [M + H]⁺ Calcd. for $\text{C}_{16}\text{H}_{24}^{79}\text{BrN}_4\text{O}_4$ 415.0981; Found: 415.0990.

1-(5-Chloropyridin-2-yl)-2,3-di(*tert*-butoxycarbonyl)guanidine (7a) – Procedure A with *N,N'*-*bis*-(*tert*-butoxycarbonyl)-*S*-methylisothiourea. Colourless crystals (35%) after recrystallisation from hexane:EtOAc. Mp. 122-124 °C, clean melt. δ_{H} (400 MHz, CDCl_3): 1.53 (s, 9H, CH_3 , Boc), 1.54 (s, 9H, CH_3 , Boc), 7.67 (dd, 1H, J 8.9, 2.6, Ar), 8.24 (d, 1H, J

2.6, Ar), 8.40 (d, 1H, J 8.9, Ar), 10.92 (broad s, 1H, NH), 11.51 (broad s, 1H, NH). δ_{C} (100 MHz, CDCl_3): 28.0 (CH_3 , Boc), 28.1 (CH_3 , Boc), 80.1 (q ^tBu , Boc), 84.1 (q ^tBu , Boc), 116.8 (CH Ar), 126.9 (q Ar), 137.7 (CH Ar), 146.6 (CH Ar), 148.9 (q Ar), 152.6 (q CO, Boc), 152.9 (q, Gua), 163.0 (q CO, Boc). ν_{max} (ATR)/ cm^{-1} : 3249 (NH), 2981, 1741, 1716 (C=O), 1633 (C=N), 1576, 1559, 1476, 1455, 1407, 1383, 1367, 1322, 1287, 1252, 1235, 1219, 1142, 1123, 1101, 1059, 1028, 1006, 967, 917, 880, 848, 837, 801, 782, 743, 728, 685. HRMS (ESI $^+$) m/z : [M + H] $^+$ Calcd. for $\text{C}_{16}\text{H}_{24}^{35}\text{ClN}_4\text{O}_4$ 371.1486; Found: 371.1489.

1-(5-Chloropyridin-2'-yl)-2,3-di(*tert*-butoxycarbonyl)-2-iminoimidazolidine (7b) – Procedure A with *N,N'*-di(*tert*-butoxycarbonyl) imidazolidine-2-thione. Colourless oil (56%). δ_{H} (400 MHz, CDCl_3): 1.38 (s, 18H, CH_3 , Boc), 3.84 (s, 4H, CH_2), 6.95 (d, 1H, J 8.7, Ar), 7.53 (dd, 1H, J 2.6, 8.7, Ar), 8.11 (d, 1H, J 2.6, Ar). δ_{C} (100 MHz, CDCl_3): 27.8 (CH_3 , Boc), 43.0 (2 CH_2), 82.9 (q ^tBu , Boc), 119.4 (CH Ar), 124.7 (q Ar), 137.3 (CH Ar), 141.8 (q Ar), 145.9 (CH Ar), 149.7 (q CO, Boc), 159.2 (q, Imi). ν_{max} (ATR)/ cm^{-1} : 2980, 2933, 2251, 1765, 1712 (C=O), 1654 (C=N), 1579, 1548, 1460, 1367, 1291, 1251, 1146, 1039, 1007, 980, 910, 843, 769, 727. HRMS (ESI $^+$) m/z : [M + Na] $^+$ Calcd. for $\text{C}_{18}\text{H}_{25}\text{N}_4\text{O}_4^{35}\text{ClNa}$ 419.1462; Found: 419.1453.

1-(5-Chloropyridin-2-yl)-2-(*tert*-butoxycarbonyl)-3-(propyl)guanidine (7h) – Procedure A with *N*-(*tert*-Butoxycarbonyl)-*N'*-propyl thiourea. Colourless oil (39%) identified as a mixture of isomers. M.p. 79-82 °C, clean melt. δ_{H} (400 MHz, CDCl_3): 1.00 (m, 3H, CH_3), 1.54 (s, 9H, CH_3 , Boc), 1.65 (app. sex, 2H, J 7.3, CH_2), 3.49 (m, 2H, CH_2), 6.82 (d, 1H, J 8.8), 7.60 (dd, 1H, J 8.8, 2.3), 8.17 (d, 1H, J 2.3), 9.77 (broad s, 1H, NH), 12.28 (broad s, 1H, NH). δ_{C} (100 MHz, CDCl_3): 11.5 (CH_3), 22.5 (CH_2), 28.2 (CH_3 , Boc), 42.6 (CH_2), 78.8 (q ^tBu , Boc), 114.2 (CH Ar), 122.8 (q Ar), 138.4 (CH Ar), 144.5 (CH Ar), 151.4 (q Ar), 157.2 (q, CN), 164.4 (q CO, Boc). ν_{max} (ATR)/ cm^{-1} : 3359 (NH), 2968, 1730 (C=O), 1645 (C=N), 1585, 1560, 1476, 1455, 1406, 1380, 1329, 1322, 1288, 1259, 1234, 1170, 1156, 1120, 1032, 980, 832, 799, 734, 689. HRMS (ESI $^+$) m/z : [M + Na] $^+$ Calcd. for $\text{C}_{14}\text{H}_{21}\text{N}_4\text{O}_2^{35}\text{ClNa}$ 335.1251; Found: 335.1246.

1-(5-Methylpyridin-2-yl)-2,3-di(*tert*-butoxycarbonyl)guanidine (8a) – Procedure A with *N,N'*-bis(*tert*-butoxycarbonyl)-*S*-methylisothiourea. White powder (71%). Mp. 139 °C, clean melt. δ_{H} (400 MHz, CDCl_3): 1.48 (s, 9H, CH_3 , Boc), 1.49 (s, 9H, CH_3 , Boc), 2.23 (s, 3H, CH_3), 7.45 (dd, 1H, J 8.4, 1.9, Ar), 8.07 (d, 1H, J 1.9, Ar), 8.20 (broad s, 1H, Ar), 10.78 (broad s, 1H, NH), 11.52 (broad s, 1H, NH). δ_{C} (100 MHz, CDCl_3): 17.8 (CH_3), 28.0 (CH_3 ,

Boc), 28.1 (CH₃, Boc), 79.7 (q ^tBu, Boc), 83.7 (q ^tBu, Boc), 115.6 (CH Ar), 129.1 (q Ar), 138.6 (CH Ar), 147.9 (CH Ar), 148.4 (q Ar), 152.7 (q CO, Boc), 153.0 (q, Gua), 163.3 (q CO, Boc). ν_{max} (ATR)/cm⁻¹: 3244 (NH), 2978, 1720 (C=O), 1632 (C=N), 1585, 1560, 1475, 1454, 1404, 1374, 1324, 1305, 1289, 1268, 1252, 1230, 1151, 1136, 1107, 1058, 1025, 882, 856, 838, 803, 758, 749, 709. HRMS (ESI⁺) m/z : [M + H]⁺ Calcd. for C₁₇H₂₇N₄O₄ 351.2032; Found: 351.2036.

1-(5-Methylpyridin-2'-yl)-2,3-di(*tert*-butoxycarbonyl)-2-iminoimidazolidine (8b) –
Procedure A with *N,N'*-di-(*tert*-butoxycarbonyl) imidazolidine-2-thione. White solid (75%). Mp. 89-91 °C, clean melt. δ_{H} (400 MHz, CDCl₃): 1.44 (s, 18H, CH₃, Boc), 2.15 (s, 3H, CH₃), 3.68 (s, 4H, CH₂), 7.34 (dd, 1H, J 8.4, 2.0, Ar), 7.85 (broad s, 1H, Ar), 7.97 (d, 1H, Ar). δ_{C} (100 MHz, CDCl₃): 17.6 (CH₃), 28.1 (CH₃, Boc), 45.2 (2 CH₂), 82.4 (q ^tBu, Boc), 112.6 (CH Ar), 126.6 (q Ar), 138.4 (CH Ar), 147.6 (CH Ar), 149.8 (q CO, Boc), 150.3 (q Ar), 152.3 (q, Imi). ν_{max} (ATR)/cm⁻¹: 3265, 2980, 2933, 2885, 1804, 1697 (C=O), 1647 (C=N), 1602, 1577, 1543, 1480, 1467, 1365, 1330, 1307, 1288, 1253, 1232, 1149, 1115, 1026, 879, 851, 840, 767, 748, 740, 701, 684. HRMS (ESI⁺) m/z : [M + H]⁺ Calcd. for C₁₉H₂₉N₄O₄ 377.2189; Found: 377.2186.

1-(5-Methylpyridin-2-yl)-2-(*tert*-butoxycarbonyl)-3-(phenyl)guanidine (8e) – Procedure A with *N*-(*tert*-Butoxycarbonyl)-*N'*-phenyl thiourea. Colourless oil (89%) identified as a mixture of isomers. δ_{H} (400 MHz, CDCl₃): 1.56 (s, 9H, CH₃, Boc), 2.33 (s, 3H, CH₃), 6.87 (d, 1H, J 7.2, Ar), 7.12 (m, 1H, Ar), 7.32-7.39 (m, 2H, Ar), 7.53 (d, 1H, J 7.7, Ar), 7.69 (d, 2H, J 8.0, Ar), 8.11 (s, 1H, Ar), 12.21 (broad s, 1H, NH), 12.41 (broad s, 1H, NH). δ_{C} (100 MHz, CDCl₃): 17.7 (CH₃), 28.4 (CH₃, Boc), 78.9 (q ^tBu, Boc), 113.1 (CH Ar), 129.0 (q Ar), 122.4 (CH Ar), 124.1 (CH Ar), 127.5 (q Ar), 128.8 (CH Ar), 139.7 (CH Ar), 145.5 (CH Ar), 150.6 (q Ar), 155.3 (q, CN), 164.2 (q CO, Boc). ν_{max} (ATR)/cm⁻¹: 2978, 1709 (C=O), 1643 (C=N), 1607, 1590, 1562, 1494, 1473, 1447, 1354, 1244, 1203, 1154, 1096, 1069, 1027, 985, 901, 808, 752, 690. HRMS (ESI⁺) m/z : [M + H]⁺ Calcd. for C₁₈H₂₃N₄O₂ 327.1821; Found: 327.1828.

1-(5-Methylpyridin-2-yl)-2-(*tert*-butoxycarbonyl)-3-(2-acetoxyethyl)guanidine (8f) –
Procedure A with *N*-(*tert*-Butoxycarbonyl)-*N'*-(2-acetoxyethyl) thiourea. Colourless oil (54%). δ_{H} (400 MHz, CDCl₃): 1.56 (s, 9H, CH₃, Boc), 2.13 (s, 3H, CH₃), 2.31 (s, 3H, CH₃), 3.83 (app. q, 2H, J 5.4, 5.1, CH₂), 4.29 (app. t, 2H, J 5.5, 5.3, CH₂), 6.80 (d, 1H, J 8.4), 7.49 (dd, 1H, J 8.4, 2.2), 8.02 (d, 1H, J 2.2), 10.45 (broad s, 1H, NH), 12.02 (broad s, 1H, NH). δ_{C}

(100 MHz, CDCl_3): 17.6 (CH_3), 20.9 (CH_3), 28.4 (CH_3 , Boc), 39.5 (CH_2), 63.3 (CH_2), 78.7 (q^tBu , Boc), 112.9 (CH Ar), 127.2 (q Ar), 139.4 (CH Ar), 145.4 (CH Ar), 150.8 (q Ar), 157.8 (q, CN), 164.1 (q CO, Boc), 170.9 (q CO). ν_{max} (ATR)/ cm^{-1} : 2926, 1742 (C=O), 1641 (C=N), 1602, 1496, 1476, 1352, 1301, 1232, 1172, 1137, 1046, 808, 741. HRMS (ESI $^+$) m/z : [M + H] $^+$ Calcd. for $\text{C}_{16}\text{H}_{25}\text{N}_4\text{O}_4$ 337.1876; Found: 337.1884.

1-(5-Methylpyridin-2-yl)-2-(*tert*-butoxycarbonyl)-3-(2-furanylmethyl)guanidine (8g) – Procedure A with *N*-(*tert*-Butoxycarbonyl)-*N'*-(2-furanylmethyl) thiourea. White solid (41%). M.p. 102-103 °C, clean melt. δ_{H} (400 MHz, CDCl_3): 1.57 (s, 9H, CH_3 , Boc), 2.28 (s, 3H, CH_3), 4.76 (d, 1H, J 4.8, CH_2), 6.30 (d, 1H, J 3.1, Ar), 6.36 (m, 1H, Ar), 6.79 (d, 1H, J 8.4, Ar), 7.41 (s, 1H, Ar), 7.47 (d, 1H, J 8.4, Ar), 8.01 (s, 1H, Ar), 10.57 (broad s, 1H, NH), 12.03 (broad s, 1H, NH). δ_{C} (100 MHz, CDCl_3): 17.2 (CH_3), 28.0 (CH_3 , Boc), 37.7 (CH_2), 78.3 (q^tBu , Boc), 106.6 (CH Ar), 109.9 (CH Ar), 112.3 (CH Ar), 126.7 (q Ar), 139.0 (CH Ar), 141.6 (CH Ar), 145.1 (CH Ar), 150.3 (q Ar), 151.1 (q Ar), 157.0 (q, CN), 163.7 (q CO, Boc). ν_{max} (ATR)/ cm^{-1} : 3005 (NH), 2963, 2981, 2929, 1640 (C=O), 1620 (C=N), 1599, 1566, 1506, 1493, 1482, 1427, 1386, 1348, 1336, 1299, 1262, 1252, 1236, 1214, 1167, 1153, 1122, 1085, 1059, 1036, 976, 964, 801, 772, 739, 698, 670. HRMS (ESI $^+$) m/z : [M + H] $^+$ Calcd. for $\text{C}_{17}\text{H}_{23}\text{N}_4\text{O}_3$ 331.1770; Found: 331.1764.

1-(5-Methylpyridin-2-yl)-2-(*tert*-butoxycarbonyl)-3-(propyl)guanidine (8h) – Procedure A with *N*-(*tert*-Butoxycarbonyl)-*N'*-propyl thiourea. White solid (63%) as a white solid. M.p. 102-104 °C. δ_{H} (600 MHz, CDCl_3): 0.98 (t, 3H, J 7.4, CH_3), 1.51 (s, 9H, CH_3 , Boc), 1.62 (app. sex, 2H, J 7.6, 7.2, CH_2), 2.24 (s, 3H, CH_3), 3.46 (m, 2H, CH_2), 6.72 (d, 1H, J 8.4, Ar), 7.42 (dd, 1H, J 8.4, 2.1, Ar), 7.98 (d, 1H, J 2.1, Ar), 10.17 (broad s, 1H, NH), 11.97 (broad s, 1H, NH). δ_{C} (150 MHz, CDCl_3): 11.5 (CH_3), 17.5 (CH_3), 22.5 (CH_2), 28.4 (CH_3 , Boc), 42.4 (CH_2), 78.4 (q^tBu , Boc), 112.7 (CH Ar), 126.7 (q Ar), 139.2 (CH Ar), 145.3 (CH Ar), 150.9 (q Ar), 157.5 (q CO, Boc), 164.2 (q, CN). ν_{max} (ATR)/ cm^{-1} : 3355 (NH), 2965, 2930, 2875, 1712 (C=O), 1638 (C=N), 1597, 1562, 1495, 1474, 1347, 1300, 1245, 1172, 1154, 1125, 1056, 1026, 961, 909, 821, 805, 774, 739, 665. HRMS (ESI $^+$) m/z : [M + Na] $^+$ Calcd. for $\text{C}_{15}\text{H}_{24}\text{N}_4\text{O}_2\text{Na}$ 315.1797; Found: 315.1792.

1-(5,6,7,8-Tetrahydroquinolin-2-yl)-2,3-di(*tert*-butoxycarbonyl)guanidine (9a) – **Procedure A** with *N,N'*-bis-(*tert*-butoxycarbonyl)-*S*-methylisothiourea. White powder (90%). Mp. 164-165 °C, clean melt. δ_{H} (400 MHz, CDCl_3): 1.52 (s, 18H, CH_3 , Boc), 1.78 (m, 2H, CH_2), 1.84 (m, 2H, CH_2), 2.70 (t, 2H, J 6.3, 6.1, CH_2), 2.78 (t, 2H, J 6.1, 6.3, CH_2), 7.35 (d,

1H, J 8.3, Ar), 8.04 (broad s, 1H, Ar), 10.64 (broad s, 1H, NH), 11.54 (broad s, 1H, NH). δ_{C} (100 MHz, CDCl_3): 22.7 (CH_2), 22.9 (CH_2), 28.00 (CH_3 , Boc), 28.02 (CH_2), 28.04 (CH_3 , Boc), 32.0 (CH_2), 79.6 (q ^tBu , Boc), 83.6 (q ^tBu , Boc), 113.6 (CH Ar), 128.3 (q Ar), 138.7 (CH Ar), 147.6 (q Ar), 152.6 (q CO, Boc), 152.0 (q, Gua), 155.4 (q Ar), 163.3 (q CO, Boc). ν_{max} (ATR)/ cm^{-1} : 3251 (NH), 2979, 1714 (C=O), 1645 (C=N), 1629, 1588, 1565, 1449, 1395, 1369, 1354, 1325, 1313, 1279, 1247, 1231, 1151, 1112, 1058, 1029, 996, 941, 899, 874, 864, 840, 804, 755, 713. HRMS (ESI $^+$) m/z : [M + H] $^+$ Calcd. for $\text{C}_{20}\text{H}_{31}\text{N}_4\text{O}_4$ 391.2345; Found: 391.2342.

1-(5,6,7,8-Tetrahydroquinolin-2'-yl)-2,3-di(*tert*-butoxycarbonyl)-2-iminoimidazolidine (9b) – Procedure A with *N,N'*-di-(*tert*-butoxycarbonyl) imidazolidine-2-thione. Colourless oil (81%). δ_{H} (400 MHz, CDCl_3): 1.44 (s, 18H, CH_3 , Boc), 1.71-1.80 (m, 4H, CH_2), 2.66 (app. t, 2H, J 5.9, 6.1, CH_2), 2.72 (app. t, 2H, J 6.1, 6.3, CH_2), 3.82 (s, 4H, CH_2), 6.75 (d, 1H, J 8.1, Ar), 7.26 (d, 1H, J 8.1, Ar). δ_{C} (100 MHz, CDCl_3): 23.0 (CH_2), 23.2 (CH_2), 27.8 (CH_3 , Boc), 28.2 (CH_2), 32.5 (CH_2), 42.7 (2 CH_2), 82.3 (q ^tBu , Boc), 115.7 (CH Ar), 125.5 (q Ar), 138.4 (CH Ar), 140.3 (q Ar), 150.0 (q Ar), 154.4 (q CO, Boc), 157.9 (q, Imi). ν_{max} (ATR)/ cm^{-1} : 2977, 2932, 1752, 1702 (C=O), 1589, 1586, 1458, 1366, 1352, 1291, 1248, 1145, 1104, 1039, 995, 977, 936, 847, 833, 821, 767, 729, 696. HRMS (ESI $^+$) m/z : [M + H] $^+$ Calcd. for $\text{C}_{22}\text{H}_{33}\text{N}_4\text{O}_4$ 417.2502; Found: 417.2494.

1-(5,6,7,8-Tetrahydroquinolin-2-yl)-2-(*tert*-butoxycarbonyl)-3-(phenyl)guanidine (9e) – Procedure A with *N*-(*tert*-Butoxycarbonyl)-*N'*-phenyl thiourea. White solid (88%) identified as a mixture of isomers. M.p. 150-152 °C. δ_{H} (400 MHz, CDCl_3): 1.58 (s, 9H, CH_3 , Boc), 1.80-1.98 (m, 4H, CH_2), 2.74 (app. t, 2H, J 6.3, 5.8, CH_2), 2.91 (app. t, 2H, J 6.4, 5.9, CH_2), 6.69 (d, 1H, J 8.1, Ar), 7.10 (t, 1H, J 7.3, Ar), 7.36 (app. t, 2H, J 8.0, 7.3, Ar), 7.39 (d, 1H, J 8.1, Ar), 7.71 (d, 2H, J 8.0, Ar), 12.09 (broad s, 1H, NH), 12.93 (broad s, 1H, NH). δ_{C} (100 MHz, CDCl_3): 22.7 (CH_2), 27.9 (CH_2), 28.4 (CH_3 , Boc), 32.1 (CH_2), 78.8 (q ^tBu , Boc), 110.8 (CH Ar), 120.7 (q Ar), 121.8 (CH Ar), 123.8 (CH Ar), 128.7 (q Ar), 128.9 (CH Ar), 139.8 (CH Ar), 150.0 (q Ar), 153.5 (q Ar, Ar), 155.3 (q, CN), 164.5 (q CO, Boc). ν_{max} (ATR)/ cm^{-1} : 2921, 2853, 1708 (C=O), 1687 (C=N), 1471, 1389, 1286, 716. HRMS (ESI $^+$) m/z : [M + H] $^+$ Calcd. for $\text{C}_{21}\text{H}_{27}\text{N}_4\text{O}_2$ 367.2134; Found: 367.2140.

1-(5,6,7,8-Tetrahydroquinolin-2-yl)-2-(*tert*-butoxycarbonyl)-3-(2-acetoxyethyl)guanidine (9f) – Procedure A with *N*-(*tert*-Butoxycarbonyl)-*N'*-(2-acetoxyethyl) thiourea. Colourless oil (69%). δ_{H} (400 MHz, CDCl_3): 1.52 (s, 9H, CH_3 , Boc), 2.10 (s, 3H, CH_3), 1.75-

1.82 (m, 2H, CH₂), 1.82-1.90 (m, 2H, CH₂), 2.67 (app. t, 2H, J 6.3, 6.2, CH₂), 2.77 (app. t, 2H, J 6.5, 6.2, CH₂), 3.81 (app. q, 2H, J 5.4, 5.4, 5.0), 4.24 (t, 2H, J 5.4, CH₂), 6.59 (d, 1H, J 8.3), 7.30 (d, 1H, J 8.3), 10.72 (broad t, 1H, J 5.0, NH), 11.90 (broad s, 1H, NH). δ_{C} (100 MHz, CDCl₃): 20.9 (CH₃), 22.7 (CH₂), 22.7 (CH₂), 27.8 (CH₂), 28.4 (CH₃, Boc), 32.2 (CH₂), 39.5 (CH₂), 63.7 (CH₂), 78.6 (q ^tBu, Boc), 110.6 (CH Ar), 126.1 (q Ar), 139.5 (CH Ar), 150.2 (q Ar), 153.4 (q Ar), 157.9 (q, CN), 164.0 (q CO, Boc), 170.7 (q CO). ν_{max} (ATR)/cm⁻¹: 2936, 1743 (C=O), 1618 (C=N), 1592, 1459, 1335, 1236, 1172, 1138, 1046, 812, 736. HRMS (ESI⁺) *m/z*: [M + H]⁺ Calcd. for C₁₉H₂₉N₄O₄ 377.2189; Found: 377.2197.

1-(5,6,7,8-Tetrahydroquinolin-2-yl)-2-(*tert*-butoxycarbonyl)-3-(2-furanylmethyl)guanidine (9g) – Procedure A with *N*-(*tert*-Butoxycarbonyl)-*N'*-(2-furanylmethyl) thiourea. White solid (65%). M.p. 79-82 °C, clean melt. δ_{H} (400 MHz, CDCl₃): 1.56 (s, 9H, CH₃, Boc), 1.74-1.87 (m, 4H, 2 CH₂), 2.66 (m, 2H, CH₂), 2.70 (m, 2H, CH₂), 4.72 (d, 1H, J 4.6, CH₂), 6.29 (d, 1H, J 2.6, Ar), 6.34-6.37 (m, 1H, Ar), 6.59 (d, 1H, J 8.2, Ar), 7.29 (d, 1H, J 8.2, Ar), 7.41 (d, 1H, J 0.9, Ar), 10.98 (broad s, 1H, NH), 11.89 (broad s, 1H, NH). δ_{C} (100 MHz, CDCl₃): 22.7 (CH₂), 22.8 (CH₂), 27.8 (CH₂), 28.5 (CH₃, Boc), 31.9 (CH₂), 38.3 (CH₂), 78.6 (q ^tBu, Boc), 106.8 (CH Ar), 110.4 (CH Ar), 110.4 (CH Ar), 126.2 (q Ar), 139.4 (CH Ar), 142.0 (CH Ar), 150.2 (q Ar), 151.5 (q Ar), 153.5 (q Ar), 157.4 (q, CN), 164.0 (q CO, Boc). ν_{max} (ATR)/cm⁻¹: 3119 (NH), 2979, 2938, 1713 (C=O), 1639 (C=N), 1614, 1597, 1585, 1561, 1507 1474, 1447, 1330, 1306, 1268, 1232, 117, 1092, 1007, 946, 884, 797, 778, 751, 734. HRMS (ESI⁺) *m/z*: [M + Na]⁺ Calcd. for C₂₀H₂₆N₄O₃Na 393.1903; Found: 393.1893.

1-[5-(Ethylamino)pyridin-2'-yl]-2,3-di(*tert*-butoxycarbonyl)-2-iminoimidazolidine (10b) – **Procedure A** with *N,N'*-di-(*tert*-butoxycarbonyl) imidazolidine-2-thione. Red liquid (35%). δ_{H} (400 MHz, CDCl₃): 1.21 (t, 3H, J 7.0, CH₃), 1.52 (s, 18H, CH₃, Boc), 3.11 (q, 2H, J 7.0, CH₂), 3.75 (s, 4H, CH₂), 5.43 (broad s, 1H, NH), 6.93 (dd, 1H, J 8.9, 3.0, Ar), 7.69 (d, 1H, 8.9, Ar), 7.80 (d, 1H, J 3.0, Ar). δ_{C} (100 MHz, CDCl₃): 14.8 (CH₃), 28.2 (CH₃, Boc), 38.9 (CH₂), 45.3 (2 CH₂), 82.4 (q ^tBu, Boc), 114.3 (CH Ar), 122.4 (CH Ar), 132.8 (CH Ar), 140.2 (q Ar), 149.9 (q Ar), 152.2 (q CO, Boc), 155.0 (q, Imi). ν_{max} (ATR)/cm⁻¹: 3375 (NH), 2977, 2933, 1804, 1740, 1712, 1698 (C=O), 1676 (C=N), 1604, 1571, 1502, 1477, 1457, 1367, 1303, 1268, 1245, 1144, 1081, 973, 848, 834, 813, 765, 721, 686. HRMS (ESI⁺) *m/z*: [M + H]⁺ Calcd. for C₂₀H₃₂N₅O₄ 406.2454; Found: 406.2450.

1-(Pyridin-3-yl)-2,3-di(*tert*-butoxycarbonyl)guanidine (11a) – Procedure A with *N,N'*-bis-(*tert*-butoxycarbonyl)-*S*-methylisothiourea. Off-white powder (89%). Mp. 136-138 °C, clean melt. δ_H (400 MHz, CDCl₃): 1.50 (s, 9H, Boc CH₃), 1.54 (s, 9H, Boc CH₃), 7.28 (dd, 1H, J 8.3, 4.1, Ar), 8.21 (dd, 1H, J 8.3, 1.5, Ar), 8.34 (d, 1H, J 4.1, Ar), 8.67 (d, 1H, J 1.5, Ar), 10.41 (broad s, 1H, NH), 11.61 (broad s, 1H, NH). δ_C (100 MHz, CDCl₃): 27.6 (CH₃, Boc), 27.6 (CH₃, Boc), 79.6 (q ¹Bu, Boc), 83.7 (q ¹Bu, Boc), 123.1 (CH Ar), 129.2 (CH Ar), 133.4 (q Ar), 142.7 (CH Ar), 145.0 (q Ar), 152.8 (q CO, Boc), 153.3 (q, Gua), 162.8 (q CO, Boc). ν_{max} (ATR)/cm⁻¹: 3146 (NH), 2981, 1725 (C=O), 1636 (C=N), 1587, 1561, 1477, 1396, 1367, 1329, 1280, 1252, 1226, 1151, 1132, 1101, 1057, 1029, 942, 883, 845, 801, 773, 746, 719, 702, 656. HRMS (ESI⁺) *m/z*: [M + H]⁺ Calcd. for C₁₆H₂₅N₄O₄ 337.1876; Found: 337.1870.

1-(Pyridin-3'-yl)-2,3-di(*tert*-butoxycarbonyl)-2-iminoimidazolidine (11b) – Procedure A with *N,N'*-di-(*tert*-butoxycarbonyl) imidazolidine-2-thione. Colourless crystals (87%). Mp. 99-101 °C, clean melt. δ_H (400 MHz, CDCl₃): 1.11 (s, 18H, CH₃, Boc), 3.62 (s, 4H, CH₂), 6.93 (dd, 1H, J 7.9, 4.6, Ar), 7.04 (d, 1H, J 7.9, Ar), 7.94 (d, 1H, J 3.9, Ar), 8.04 (broad s, 1H, Ar). δ_C (100 MHz, CDCl₃): 27.2 (CH₃, Boc), 42.7 (2 CH₂), 82.3 (q ¹Bu, Boc), 122.6 (CH Ar), 127.1 (CH Ar), 140.5 (q Ar), 142.5 (CH Ar), 142.5 (CH Ar), 144.5 (q CO, Boc), 149.1 (q, Imi). ν_{max} (ATR)/cm⁻¹: 2979, 2934, 1758, 1702 (C=O), 1670 (C=N), 1579, 1476, 1458, 1412, 1367, 1297, 1248, 1144, 1041, 1020, 977, 913, 846, 808, 767, 727, 709. HRMS (ESI⁺) *m/z*: [M + H]⁺ Calcd. for C₁₈H₂₇N₄O₄ 363.2032; Found: 363.2033.

1-(6-Chloropyridin-3-yl)-2,3-di(*tert*-butoxycarbonyl)guanidine (12a) – Procedure A with *N,N'*-bis-(*tert*-butoxycarbonyl)-*S*-methylisothiourea. White powder (79%). Mp. 118-120 °C, clean melt. δ_H (400 MHz, CDCl₃): 1.50 (s, 9H, CH₃, Boc), 1.55 (s, 9H, CH₃, Boc), 7.31 (d, 1H, J 8.7, Ar), 8.22 (dd, 1H, J 8.7, 2.8, Ar), 8.47 (d, 1H, J 2.8, Ar), 10.44 (broad s, 1H, NH), 11.60 (broad s, 1H, NH). δ_C (100 MHz, CDCl₃): 28.0 (CH₃, Boc), 28.1 (CH₃, Boc), 80.1 (q ¹Bu, Boc), 84.4 (q ¹Bu, Boc), 124.1 (CH Ar), 132.5 (CH Ar), 133.0 (q Ar), 142.7 (CH Ar), 146.3 (q Ar), 153.3 (q CO, Boc), 153.6 (q, Gua), 163.1 (q CO, Boc). ν_{max} (ATR)/cm⁻¹: 3249 (NH), 2981, 1741, 1716 (C=O), 1633 (C=N), 1576, 1559, 1476, 1455, 1407, 1383, 1367, 1322, 1287, 1252, 1235, 1219, 1142, 1123, 1101, 1059, 1028, 1006, 967, 917, 880, 848, 837, 801, 782, 743, 728, 685. HRMS (ESI⁺) *m/z*: [M + H]⁺ Calcd. for C₁₆H₂₄³⁵ClN₄O₄ 371.1486; Found: 371.1488.

1-(6-Methylpyridin-3-yl)-2,3-di(*tert*-butoxycarbonyl)guanidine (13a) – Procedure A with *N,N'*-bis-(*tert*-butoxycarbonyl)-*S*-methylisothiourea. White powder (88%). Mp. 102 °C, clean

melt. δ_H (400 MHz, $CDCl_3$): 1.48 (s, 9H, Boc CH_3), 1.53 (s, 9H, Boc CH_3), 2.50 (s, 3H, CH_3), 7.12 (d, 1H, J 8.0, Ar), 8.03 (d, 1H, J 8.0, Ar), 8.53 (s, 1H, Ar), 10.28 (broad s, 1H, NH), 11.61 (broad s, 1H, NH). δ_C (100 MHz, $CDCl_3$): 23.8 (CH_3), 28.0 (CH_3 , Boc), 28.1 (CH_3 , Boc), 79.8 (q t^Bu , Boc), 84.0 (q t^Bu , Boc), 123.0 (CH Ar), 130.3 (CH Ar), 131.1 (q Ar), 142.7 (CH Ar), 153.3 (q Ar), 153.8 (q CO, Boc), 154.4 (q, Gua), 163.3 (q CO, Boc). ν_{max} (ATR)/ cm^{-1} : 3244 (NH), 2978, 1720 (C=O), 1632 (C=N), 1585, 1560, 1475, 1454, 1404, 1374, 1324, 1305, 1289, 1268, 1252, 1230, 1151, 1136, 1107, 1058, 1025, 882, 856, 838, 803, 758, 749, 709. HRMS (ESI $^+$) m/z : [M + H] $^+$ Calcd. for $C_{17}H_{27}N_4O_4$ 351.2032; Found: 351.2028.

1-(5,6,7,8-tetrahydroquinolin-3-yl)-2,3-di(*tert*-butoxycarbonyl)guanidine (14a) – Procedure A with *N,N'*-bis-(*tert*-butoxycarbonyl)-S-methylisothiourea. White powder (87%). Mp. 124-125 °C, clean melt. δ_H (400 MHz, $CDCl_3$): 1.50 (s, 9H, CH_3 , Boc), 1.55 (s, 9H, CH_3 , Boc), 1.77-1.83 (m, 2H, CH_2), 1.86-1.92 (m, 2H, CH_2), 2.80 (app. t, 2H, J 6.4, 6.1, CH_2), 2.89 (app. t, 2H, J 6.4, CH_2), 7.79 (d, 1H, J 2.0, Ar), 8.44 (d, 1H, J 2.0, Ar), 10.25 (broad s, 1H, NH), 11.63 (broad s, 1H, NH). δ_C (100 MHz, $CDCl_3$): 22.5 (CH_2), 23.1 (CH_2), 28.1 (CH_3 , Boc), 28.1 (CH_3 , Boc), 28.9 (CH_2), 32.0 (CH_2), 79.8 (q t^Bu , Boc), 84.0 (q t^Bu , Boc), 130.7 (CH Ar), 131.1 (q Ar), 132.4 (q Ar), 140.8 (CH Ar), 153.3 (q CO, Boc), 153.7 (q Ar), 153.9 (q, Gua), 163.3 (q CO, Boc). ν_{max} (ATR)/ cm^{-1} : 3250 (NH), 2982 (NH), 2933, 1725 (C=O), 1634 (C=N), 1596, 1552, 1467, 1400, 1368, 1328, 1280, 1249, 1228, 1153, 1105, 1059, 1032, 943, 909, 877, 855, 808, 760, 721, 711. HRMS (ESI $^+$) m/z : [M + H] $^+$ Calcd. for $C_{20}H_{31}N_4O_4$ 391.2345; Found: 391.2350.

1-(5,6,7,8-Tetrahydroquinolin-3'-yl)-2,3-di(*tert*-butoxycarbonyl)-2-iminoimidazolidine (14b) – Procedure A with *N,N'*-di-(*tert*-butoxycarbonyl) imidazolidine-2-thione. White solid (85%). Mp. 128-131 °C, clean melt. δ_H (400 MHz, $CDCl_3$): 1.21 (s, 18H, CH_3 , Boc), 1.60-1.66 (m, 2H, CH_2), 1.68-1.75 (m, 2H, CH_2), 2.57 (app. t, 2H, J 6.0, 6.3, CH_2), 2.71 (app. t, 2H, J 6.0, 6.3, CH_2), 3.71 (s, 4H, CH_2), 6.83 (d, 1H, J 2.4, Ar), 7.94 (d, 1H, J 2.4, Ar). δ_C (100 MHz, $CDCl_3$): 22.7 (CH_2), 23.3 (CH_2), 27.8 (CH_3 , Boc), 28.7 (CH_2), 31.7 (CH_2), 43.1 (2 CH_2), 82.8 (q t^Bu , Boc), 128.1 (CH Ar), 131.3 (q Ar), 140.2 (q Ar), 140.5 (CH Ar), 142.2 (q Ar), 149.9 (q CO, Boc), 150.6 (q, Imi). ν_{max} (ATR)/ cm^{-1} : 2979, 2921, 2858, 1752, 1754, 1719(C=O), 1649 (C=N), 1594, 1560, 1465, 1368, 1333, 1293, 1257, 1233, 1202, 1187, 1107, 1037, 1005, 977, 947, 921, 844, 823, 786, 767, 746, 735, 712, 700, 682. HRMS (ESI $^+$) m/z : [M + H] $^+$ Calcd. for $C_{22}H_{33}N_4O_4$ 417.2502; Found: 417.2496.

1-[6-(Ethylamino)pyridin-3-yl]-2,3-di(*tert*-butoxycarbonyl)guanidine (15a) – Procedure A with *N,N'*-bis(*tert*-butoxycarbonyl)-*S*-methylisothiourea. Colourless crystals (91%). Mp. 136-138 °C, clean melt. δ_H (400 MHz, $CDCl_3$): 1.27 (t, 3H, J 7.0, CH_3), 1.50 (s, 9H, CH_3 , Boc), 1.56 (s, 9H, CH_3 , Boc), 3.31 (m, 2H, CH_2), 4.44 (t, 1H, J 5.3, NH, NHEt), 6.40 (d, 1H, J 8.9, Ar), 7.77 (dd, 1H, J 8.9, 2.6, Ar), 8.15 (d, 1H, J 2.6, Ar), 10.03 (broad s, 1H, NH), 11.65 (broad s, 1H, NH). δ_C (100 MHz, $CDCl_3$): 14.9 (CH_3), 28.1 (CH_3 , Boc), 28.2 (CH_3 , Boc), 37.2 (CH_2), 79.5 (q tBu , Boc), 83.6 (q tBu , Boc), 106.5 (CH Ar), 123.7 (q Ar), 133.6 (CH Ar), 142.7 (CH Ar), 153.4 (q CO, Boc), 154.2 (q, Gua), 156.5 (q Ar), 163.6 (q CO, Boc). ν_{max} (ATR)/cm⁻¹: 3285 (NH), 3269 (NH), 3124 (NH), 2976, 2932, 1792, 1722 (C=O), 1605 (C=N), 1561, 1517, 1475, 1448, 1389, 1325, 1280, 1246, 1227, 1150, 1122, 1105, 1059, 954, 883, 843, 814, 763. HRMS (ESI⁺) *m/z*: [M + H]⁺ Calcd. for $C_{18}H_{30}N_5O_4$ 380.2298; Found: 380.2291.

1-(6-(Ethylamino)pyridin-3'-yl)-2,3-di(*tert*-butoxycarbonyl)-2-iminoimidazolidine (15b) – Procedure A with *N,N'*-di(*tert*-butoxycarbonyl) imidazolidine-2-thione. White solid (64%). Mp. 121-123 °C, clean melt. δ_H (400 MHz, $CDCl_3$): 0.98 (t, 3H, J 7.1, CH_3), 1.14 (s, 18H, CH_3 , Boc), 3.04 (q, 2H, J 7.1, CH_2), 3.59 (s, 4H, CH_2), 4.43 (broad s, 1H, NH), 6.12 (d, 1H, J 8.8, Ar), 6.95 (dd, 1H, 8.8, 2.6, Ar), 7.63 (dd, 1H, J 2.6, 0.3, Ar). δ_C (100 MHz, $CDCl_3$): 14.7 (CH_3), 27.7 (CH_3 , Boc), 37.0 (CH_2), 43.0 (2 CH_2), 82.4 (q tBu , Boc), 106.1 (CH Ar), 130.6 (CH Ar), 135.2 (q Ar), 139.0 (q Ar), 141.0 (CH Ar), 150.0 (q CO, Boc), 154.9 (q, Imi). ν_{max} (ATR)/cm⁻¹: 3375 (NH), 2977, 2933, 1804, 1740, 1712 (C=O), 1698, 1676 (C=N), 1604, 1571, 1502, 1477, 1457, 1367, 1303, 1268, 1245, 1144, 1081, 973, 848, 834, 813, 765, 721, 686. HRMS (ESI⁺) *m/z*: [M + H]⁺ Calcd. for $C_{20}H_{32}N_5O_4$ 406.2454; Found: 406.2445.

N-Phenyl-1,4-dihydroquinazolin-2-amine (22i) – Procedure C with *S*-Methyl-*N*-phenyl dithiocarbamate. White solid (76%). M.p. 127-128 °C, clean melt. δ_H (400 MHz, $CDCl_3$): 4.87 (d, 2H, J 5.5, CH_2), 6.25 (broad s, 1H, NH), 6.67 (m, 2H, Ar), 7.04 (dd, J 7.7, 1.4, Ar), 7.13 (td, 1H, J 7.7, 1.4, Ar), 7.21 (dd, 2H, J 7.4, 1.1, Ar), 7.27 (t, 1H, J 7.7, Ar), 7.39 (t, 2H, J 7.4, Ar), 8.23 (broad s, 1H, NH). δ_C (100MHz, $CDCl_3$): 47.4 (CH_2), 115.8 (CH Ar), 117.8 (CH Ar), 120.5 (q Ar), 125.1 (CH Ar), 127.3 (CH Ar), 129.5 (CH Ar), 130.2 (CH Ar), 130.6 (CH Ar), 135.9 (q Ar), 145.7 (q Ar), 179.9 (q, CN). ν_{max} (ATR)/cm⁻¹: 3469, 3358 (NH), 3168 (NH), 3005, 1619 (C=N), 1592, 1524, 1492 (C=N), 1455, 1425, 1352, 1315, 1299, 1266, 1242, 1197, 1175, 1112, 1071, 1028, 965, 746, 691. HRMS (ESI⁺) *m/z*: [M + H]⁺ Calcd. for $C_{14}H_{14}N_3$ 224.1188; Found: 224.1186.

N-(2-acetoxyethyl)-1,4-dihydroquinazolin-2-amine (22j) – Procedure C with *S*-Methyl-*N*-(2-acetoxyethyl) dithiocarbamate. White solid (60%). M.p. 56-58 °C, clean melt. δ_H (400 MHz, CDCl₃): 1.94 (s, 3H, CH₃), 3.65 (broad s, 2H, CH₂), 4.07 (t, 2H, J 5.3, CH₂), 4.22 (broad s, 1H, NH), 4.54 (broad s, 2H, CH₂), 6.61 (broad s, NH), 6.64 (m, 1H, Ar), 6.71 (app. t, 1H, J 5.4, Ar), 6.96 (d, 1H, J 7.3, Ar), 7.06 (td, 1H, J 7.6, 1.3, Ar). δ_C (100MHz, CDCl₃): 20.9 (CH₃), 43.5 (CH₂), 46.0 (CH₂), 63.1 (CH₂), 116.0 (CH Ar), 121.4 (q Ar), 118.4 (CH Ar), 129.3 (CH Ar), 130.5 (CH Ar), 145.2 (q Ar), 171.5 (q CO), 181.9 (q, CN). ν_{max} (ATR)/cm⁻¹: 3376, 3185 (NH), 3025 (NH), 2956, 2926, 1720 (C=O), 1632 (C=N), 1607, 1586, 1545, 1494, 1458, 1445, 1382, 1361, 1335, 1315, 1282, 1253, 1216, 1163, 1145, 1085, 1065, 1044, 1023, 924, 866, 813, 790, 755, 715, 676. HRMS (ESI⁺) *m/z*: [M + H]⁺ Calcd. for C₁₂H₁₆N₃O₂ 234.1243; Found: 234.1239.

N-(2-Furanylmethyl)-1,4-dihydroquinazolin-2-amine (22k) – Procedure C with *S*-Methyl-*N*-(2-furanylmethyl) dithiocarbamate. Yellow solid (63%). M.p. 69-71 °C, clean melt. δ_H (400 MHz, CDCl₃): 4.57 (s, 2H, CH₂), 4.60 (s, 2H, CH₂), 6.23 (d, 1H, J 3.1, Ar), 6.30 (app. t, 1H, J 2.4, Ar), 6.32 (broad s, 1H, NH), 6.62 (d, 1H, J 7.6, Ar), 6.68 (t, 1H, J 7.4, Ar), 6.73 (t, 1H, J 5.1, NH), 6.94 (d, 1H, J 7.4, Ar), 7.10 (t, 1H, J 7.6, Ar), 7.32 (app. t, 1H, J 0.7, Ar). δ_C (100MHz, CDCl₃): 41.4 (CH₂), 46.2 (CH₂), 108.1 (CH Ar), 110.6 (CH Ar), 116.1 (CH Ar), 118.6 (CH Ar), 121.6 (q Ar), 129.4 (CH Ar), 130.7 (CH Ar), 142.3 (CH Ar), 145.1 (q Ar), 150.6 (q Ar), 181.5 (q, CN). ν_{max} (ATR)/cm⁻¹: 3256 (NH), 2937, 1673, 1633, 1609 (C=N), 1542, 1489, 1451, 1376, 1332, 1197, 1147, 1092, 1054, 1045, 1011, 884, 833, 751, 725, 669, 658. HRMS (ESI⁺) *m/z*: [M + H]⁺ Calcd. for C₁₃H₁₄N₃O 228.1137; Found: 228.1131.

N-(*n*-Propyl)-1,4-dihydroquinazolin-2-amine (22l) – Procedure C with *S*-Methyl-*N*-propyl dithiocarbamate. White solid (81%). M.p. 56-58 °C, clean melt. δ_H (400 MHz, CDCl₃): 0.88 (t, 3H, J 7.3, CH₃), 1.53 (app. s, 2H, J 7.3, CH₂), 3.28 (broad s, 1H, NH), 4.23 (broad s, 2H, CH₂), 4.64 (broad s, 2H, CH₂), 6.34 (broad s, NH), 6.62-6.70 (m, 2H, Ar), 7.00 (d, 1H, J 7.3, Ar), 7.09 (t, 1H, J 7.6, 1.3, Ar). δ_C (100MHz, CDCl₃): 11.4 (CH₃), 22.2 (CH₂), 46.0 (CH₂), 46.4 (CH₂), 116.0 (CH Ar), 118.4 (CH Ar), 121.3 (q Ar), 129.4 (CH Ar), 130.6 (CH Ar), 145.3 (q Ar), 181.1 (q, CN). ν_{max} (ATR)/cm⁻¹: 3224 (NH), 3063 (NH), 2961, 2930, 2873, 1627 (C=N), 1605, 1546, 1495, 1457, 1376, 1335, 1288, 1264, 1227, 1156, 1101, 1063, 944, 870, 749. HRMS (ESI⁺) *m/z*: [M + H]⁺ Calcd. for C₁₁H₁₆N₃ 190.1344; Found: 190.1932.

N-(2-acetoxyethyl)-1,4-dihydropyrido[2,3-*d*]pyrimidin-2-amine (23j) – Procedure C. Yellow oil (64%). δ_H (400 MHz, CDCl₃): 1.92 (s, 3H, CH₃), 3.70 (broad s, 2H, CH₂), 4.09

(m, 2H, CH₂) 4.62 (s, 2H, CH₂), 6.50 (t, 1H, J 4.0, 8.0, Ar), 6.81 (broad s, 1H, NH), 7.00 (broad s, 1H, NH), 7.29 (d, 1H, J 8.0, Ar), 7.80 (d, 1H, J 4.0, Ar). δ_{C} (100 MHz, CDCl₃): 20.8 (CH₃), 43.4 (CH₂), 45.6 (CH), 59.8 (CH₂), 113.6 (CH Ar), 116.2 (q Ar), 138.4 (CH Ar), 147.0 (CH Ar), 151.3 (q Ar), 171.4 (q CO), 182.7 (q CN). ν_{max} (ATR)/cm⁻¹: 3314 (NH), 2926, 1725 (C=O), 1622, 1596, 1543, 1446, 1367, 1224, 1977, 1040, 952, 773. HRMS (ESI⁺) *m/z*: [M + H]⁺ Calcd. for C₁₁H₁₅N₄O₂ 235.1195; Found: 235.1199.

N-(Furan-2-ylmethyl)-1,4-dihydropyrido[2,3-*d*]pyrimidin-2-amine (23k) – Procedure C. Yellow solid (51%). M.p. 185°C, clean melt. δ_{H} (400 MHz, CDCl₃): 4.63 (s, 2H, CH₂), 4.81 (s, 2H, CH₂), 6.23 (d, 1H, J 4.0, Ar), 6.26 (d, 1H, J 4.0, Ar), 6.50 (t, 1H, J 4.0, Ar), 6.59 (broad s, 1H, NH), 6.90 (broad s, 1H, NH), 7.25 (m, 2H, Ar), 7.83 (d, 1H, J 4.0, Ar). δ_{C} (100 MHz, CDCl₃): 41.4 (CH₂), 43.1 (CH₂), 107.1 (CH Ar), 108.1 (CH Ar), 113.1 (CH Ar), 114.2 (q Ar), 136.6 (CH Ar), 142.1 (CH Ar), 147.5 (CH Ar), 150.8 (q Ar), 171.1 (q Ar), 182.7 (q CN). ν_{max} (ATR)/cm⁻¹: 3235 (NH), 2921, 1650, 1598, 1534, 1501, 1488, 1443, 1336, 1328, 1245, 1189, 1098, 1035, 926, 883, 807, 770. HRMS (ESI⁺) *m/z*: [M + H]⁺ Calcd. for C₁₂H₁₃N₄O 229.1089; Found: 229.1090.

N-(1,3-Benzodioxol-5-ylmethyl)-1,4-dihydropyrido[2,3-*d*]pyrimidin-2-amine (23m) – Procedure C. Yellow oil (39%). δ_{H} (400 MHz, CDCl₃): 4.46 (broad s, 2H, CH₂), 4.57 (s, 2H, CH₂), 5.82 (s, 2H, CH₂), 6.44 (t, 1H, J 4.0, Ar), 6.62 (s, 2H, Ar), 6.67 (s, 1H, Ar), 6.80 (broad s, 1H, NH), 7.05 (broad s, 1H, NH), 7.20 (d, 1H, J 4.0, Ar), 7.73 (d, 1H, J 4.0, Ar). δ_{C} (100 MHz, CDCl₃): 45.6 (CH₂), 48.0 (CH₂), 101.0 (CH₂), 108.2 (CH Ar), 108.9 (CH Ar), 113.4 (CH Ar), 116.4 (q Ar), 120.8 (CH Ar), 131.3 (q Ar), 138.4 (CH Ar), 146.8 (CH Ar), 146.9 (q Ar), 147.8 (q Ar), 157.1 (q Ar), 182.2 (q CN). ν_{max} (ATR)/cm⁻¹: 3229 (NH), 2921, 2852, 1783, 1653, 1543, 1500, 1488, 1443, 1377, 1327, 1245, 1097, 1037, 924, 887, 805, 769. HRMS (ESI⁺) *m/z*: [M + H]⁺ Calcd. for C₁₅H₁₅N₄O₂ 283.1191; Found: 283.1195.

5. Yields obtained for all compounds prepared

Table S1. Yields (%) of purified material) obtained in the preparation of the Boc-protected derivatives (stage A) and final hydrochloride salts (stage B) starting from aminopyridines.

Cmpd	Structure	A	Cmpd	Structure	B
5a		79	5c		71
6a		80	6c		74
7a		35	7c		85
8a		71	8c		84
9a		90	9c		87
11a		89	11c		85
12a		79	12c		92
13a		88	13c		82
14a		87	14c		87

15a		91	15c		99
5b		56	5d		92
7b		56	7d		96
8b		75	8d		93
9b		81	9d		93
10b		35	10d		93
11b		87	11d		98
14b		85	14d		91
15b		64	15d		95
5e		63	5i		90

8e		89	8i		86
9e		88	9i		86
5f		43	5j		83
8f		54	8j		87
9f		69	9j		81
5g		61	5k		82
8g		41	8k		95
9g		65	9k		86
7h		39	7l		93
8h		63	8l		90


Table S2. Yields (% of purified material) obtained in the preparation of the neutral derivatives **19-25m** (stage A) and final hydrochloride salts **19-25n** (stage B).

Cmpd	Structure	A	Cmpd	Structure	B
22i		76	19i		93 ^a
22j		60	19j		95 ^b
22k		63	19k		30 ^a
22l		81	19l		90 ^a
23j		64	20j		98 ^b
23k		51	20k		86 ^a
23m		39	20m		26 ^a


^a 4M HCl in 1,4-dioxane, ^b 1.25M HCl in CH₃OH.

6. NMR spectra of final hydrochloride salts


1-(Pyridin-2-yl)guanidine hydrochloride (5c)




1-(Pyridin-2'-yl)-2-iminoimidazolidine hydrochloride (5d)




1-(Pyridin-2-yl)-3-(phenyl)guanidine hydrochloride (5i)




1-(Pyridin-2-yl)-3-(2-hydroxyethyl)guanidine hydrochloride (5j)




1-(Pyridin-2-yl)-3-(2-furanylmethyl)guanidine hydrochloride (5k)




1-(5-Bromopyridin-2-yl)guanidine hydrochloride (6c)




1-(5-Chloropyridin-2-yl)guanidine hydrochloride (7c)




1-(5-Chloropyridin-2'-yl)-2-iminoimidazolidine hydrochloride (7d)




1-(5-Chloropyridin-2-yl)-3-(propyl)guanidine hydrochloride (71)




1-(5-Methylpyridin-2-yl)guanidine hydrochloride (8c)




1-(5-Methylpyridin-2'-yl)-2-iminoimidazolidine hydrochloride (8d)




1-(5-Methylpyridin-2-yl)-3-(phenyl)guanidine hydrochloride (8i)




1-(5-Methylpyridin-2-yl)-3-(2-hydroxyethyl)guanidine hydrochloride (8j)




1-(5-Methylpyridin-2-yl)-3-(2-furanyl methyl)guanidine hydrochloride (8k)




1-(5-Methylpyridin-2-yl)-3-(propyl)guanidine hydrochloride (8l)




1-(5,6,7,8-Tetrahydroquinolin-2-yl)guanidine hydrochloride (9c)




1-(5,6,7,8-Tetrahydroquinolin-2'-yl)-2-iminoimidazolidine hydrochloride (9d)




1-(5,6,7,8-Tetrahydroquinolin-2-yl)-3-(phenyl)guanidine hydrochloride (9i)




1-(5,6,7,8-Tetrahydroquinolin-2-yl)-3-(2-hydroxyethyl)guanidine hydrochloride (9j)




1-(5,6,7,8-Tetrahydroquinolin-2-yl)-3-(2-furanylmethyl)guanidine hydrochloride (9k)




1-[5-(Ethylamino)pyridin-2-yl]guanidine hydrochloride (10c)




1-[5-(Ethylamino)pyridin-2'-yl]2-iminoimidazolidine hydrochloride (10d)




1-(Pyridin-3-yl)guanidine hydrochloride (11c)




1-(Pyridin-3'-yl)-2-iminoimidazolidine hydrochloride (11d)




1-(6-Chloropyridin-3-yl)guanidine hydrochloride (12c)




1-(6-Methylpyridin-3-yl)guanidine hydrochloride (13c)




1-(5,6,7,8-Tetrahydroquinolin-3-yl)guanidine hydrochloride (14c)




1-(5,6,7,8-Tetrahydroquinolin-3'-yl)-2-iminoimidazolidine hydrochloride (14d)




1-[6-(*N*-ethylamino)pyridin-3-yl]guanidine hydrochloride (15c)




1-(6-(Ethylamino)pyridin-3'-yl)-2-iminoimidazolidine hydrochloride (15d)




1-(5-Nitropyridin-2-yl)guanidine hydrochloride (17c)





1-(5-Aminopyridin-2-yl)guanidine hydrochloride (18c)




N-Phenyl-1,4-dihydroquinazolin-2-amine hydrochloride (19i)




N-(2-hydroxyethyl)-1,4-dihydroquinazolin-2-amine hydrochloride (19j)





N-(Furan-2-yl)-1,4-dihydroquinazolin-2-amine hydrochloride (19k)





N-(*n*-Propyl)-1,4-dihydroquinazolin-2-amine hydrochloride (19i)





N-(2-hydroxyethyl)-1,4-dihydropyrido[2,3-d]pyrimidin-2-amine hydrochloride (20j)



N-(furan-2-ylmethyl)-1,4-dihydropyrido[2,3-d]pyrimidin-2-amine hydrochloride (20k)



N-(1,3-benzodioxol-5-ylmethyl)-1,4-dihdropyrido[2,3-d]pyrimidin-2-amine hydrochloride
(20m)




7. HPLC spectra of final hydrochloride salts

1-(Pyridin-2-yl)guanidine hydrochloride (5c)

Chromatogram : Gradient1_12_01_2011
17_53_40_channel6

System : HPLC-PDA
Method : NOT DEFINED
User : Daniel
Acquired : 12/01/2011 17:55:29
Processed : 03/02/2011 14:56:28
Printed : 03/02/2011 14:58:33



Peak results :

Index	Name	Time (Min)	Quantity (% Area)	Height (mAU)	Area (mAU Min)	Area %
1	UNKNOWN	13.81	0.07	3.2	0.4	0.07%
2	UNKNOWN	14.13	0.03	0.9	0.2	0.02%
3	UNKNOWN	14.63	0.05	0.9	0.6	0.002
4	UNKNOWN	15.00	0.01	0.6	0.1	0.0009
5	UNKNOWN	16.81	97.25	349.1	547.2	97.25%
6	UNKNOWN	18.02	0.01	0.4	0.0	0.008
7	UNKNOWN	20.05	0.01	0.4	0.0	0.005
8	UNKNOWN	20.29	0.01	0.7	0.1	0.010
9	UNKNOWN	20.48	0.04	1.5	0.2	0.04%
10	UNKNOWN	21.12	0.01	0.4	0.1	0.009
11	UNKNOWN	21.58	0.00	0.3	0.0	0.004
12	UNKNOWN	22.07	0.01	0.4	0.0	0.005
13	UNKNOWN	22.44	0.08	2.4	0.5	0.083
14	UNKNOWN	22.73	0.05	1.4	0.3	0.051
15	UNKNOWN	23.41	0.01	0.3	0.0	0.006
16	UNKNOWN	25.88	0.71	17.8	4.6	0.714
17	UNKNOWN	26.89	0.29	5.0	1.6	0.520
18	UNKNOWN	31.90	0.18	5.2	1.0	0.182
19	UNKNOWN	32.04	0.24	5.4	1.4	0.244
20	UNKNOWN	32.96	0.13	4.2	0.7	0.128
21	UNKNOWN	32.58	0.04	3.2	0.2	0.044
22	UNKNOWN	32.82	0.05	2.8	0.3	0.045
23	UNKNOWN	32.72	0.04	2.4	0.2	0.039
24	UNKNOWN	32.97	0.11	2.5	0.6	0.107
25	UNKNOWN	33.33	0.20	4.8	1.1	0.198
26	UNKNOWN	33.46	0.02	1.4	0.1	0.021
27	UNKNOWN	33.97	0.01	0.4	0.0	0.008
28	UNKNOWN	34.08	0.01	0.6	0.1	0.009
29	UNKNOWN	34.73	0.05	6.9	0.1	0.026
30	UNKNOWN	34.92	0.06	6.4	0.0	0.004
31	UNKNOWN	34.98	0.01	0.4	0.0	0.005


Page

1-(Pyridin-2'-yl)-2-iminoimidazolidine hydrochloride (5d)

Chromatogram : bki283-2-iml-pyr.HCl_channel1

System : HPLC-PDA
Method : OneIdent1
User : Daniel

Acquired : 25/07/2011 15:03:10
Processed : 25/07/2011 17:24:37
Printed : 25/07/2011 17:24:47



Peak results :

Index	Name	Time (Min)	Quantity (% Area)	Height (mAU)	Area (mAU.Min)	Area %
1	UNKNOWN	3.84	0.04	18	0.1	0.038
2	UNKNOWN	3.79	0.02	9	0.1	0.017
3	UNKNOWN	3.98	0.03	9	0.1	0.033
4	UNKNOWN	4.47	0.07	18	0.3	0.067
5	UNKNOWN	5.08	0.05	17	0.2	0.052
6	UNKNOWN	5.35	0.04	13	0.1	0.038
7	UNKNOWN	5.56	0.03	8	0.1	0.029
8	UNKNOWN	8.12	0.06	14	0.2	0.063
9	UNKNOWN	8.43	0.08	20	0.3	0.078
10	UNKNOWN	8.59	0.01	8	0.1	0.015
11	UNKNOWN	13.87	0.10	15	0.4	0.101
12	UNKNOWN	18.98	0.02	8	0.1	0.023
13	UNKNOWN	17.22	0.01	8	0.0	0.015
14	UNKNOWN	17.81	0.02	8	0.1	0.024
15	UNKNOWN	17.93	0.04	14	0.1	0.038
16	UNKNOWN	18.05	0.01	8	0.0	0.008
17	UNKNOWN	18.26	0.04	14	0.2	0.043
18	UNKNOWN	18.80	97.24	455.8	387.9	97.239
52	UNKNOWN	20.41	0.15	81	0.6	0.151
19	UNKNOWN	21.11	0.01	8	0.1	0.015
20	UNKNOWN	21.33	0.03	12	0.1	0.034
53	UNKNOWN	21.58	0.01	10	0.0	0.009
21	UNKNOWN	21.85	0.08	27	0.3	0.082
22	UNKNOWN	22.24	0.01	8	0.0	0.012
23	UNKNOWN	22.41	0.01	8	0.0	0.011
24	UNKNOWN	22.77	0.05	11	0.2	0.048
25	UNKNOWN	22.92	0.05	18	0.2	0.053
26	UNKNOWN	23.25	0.02	8	0.1	0.015
27	UNKNOWN	23.48	0.10	23	0.4	0.098
28	UNKNOWN	24.32	0.01	8	0.0	0.007
29	UNKNOWN	24.61	0.01	8	0.0	0.008


1-(Pyridin-2-yl)-3-(phenyl)guanidine hydrochloride (5i)

Chromatogram :

ssmmmm12-pyr-gua-pehnyl.HCl_channel1

System : HPLC-PDA
Method : Gradient1
User : Daniel


Acquired : 23/11/2011 13:48:02
Processed : 23/11/2011 14:35:31
Printed : 23/11/2011 14:36:21



Peak results :

Index	Name	Time [Min]	Quantity [% Area]	Height [mAU]	Area [mAU.Min]	Area [%]
1	UNKNOWN	5.69	0.06	10.2	2.2	0.061
2	UNKNOWN	23.15	0.16	26.1	5.6	0.156
3	UNKNOWN	24.21	97.59	2594.5	3500.7	97.588
4	UNKNOWN	25.71	1.15	211.4	41.2	1.149
5	UNKNOWN	25.97	0.41	128.9	14.9	0.414
6	UNKNOWN	26.12	0.34	83.2	12.1	0.338
7	UNKNOWN	28.07	0.01	4.3	0.5	0.015
8	UNKNOWN	31.00	0.28	46.3	10.0	0.278
Total			100.00	3104.9	3587.2	100.000

1-(Pyridin-2-yl)-3-(2-hydroxyethyl)guanidine hydrochloride (5j)



Peak results :

Index	Name	Time (Min)	Quantity (% Area)	Height (mAU)	Area (mAU Min)	Area %
1	UNKNOWN	14.21	0.02	0.6	0.1	0.017
2	UNKNOWN	16.11	0.02	0.6	0.1	0.018
3	UNKNOWN	17.05	0.01	0.5	0.1	0.012
4	UNKNOWN	17.15	0.01	0.5	0.1	0.013
5	UNKNOWN	17.44	0.08	1.4	0.4	0.060
6	UNKNOWN	18.19	0.01	0.6	0.1	0.013
7	UNKNOWN	18.28	0.01	0.5	0.1	0.008
8	UNKNOWN	18.65	0.01	0.4	0.1	0.010
9	UNKNOWN	21.07	0.02	0.9	0.1	0.021
10	UNKNOWN	22.11	0.04	1.1	0.2	0.046
11	UNKNOWN	22.56	0.04	1.3	0.2	0.036
12	UNKNOWN	22.87	0.01	0.6	0.1	0.010
13	UNKNOWN	24.13	0.01	0.4	0.1	0.009
14	UNKNOWN	26.65	1.81	31.7	8.0	1.811
15	UNKNOWN	27.31	0.10	2.3	0.4	0.067
16	UNKNOWN	28.04	0.04	1.2	0.2	0.036
17	UNKNOWN	31.84	0.03	0.7	0.1	0.029
18	UNKNOWN	32.56	0.09	1.2	0.4	0.086
19	UNKNOWN	33.32	0.05	0.7	0.2	0.047
20	UNKNOWN	37.48	0.04	1.0	0.2	0.043
21	UNKNOWN	40.88	0.35	17.8	1.5	0.348
22	UNKNOWN	40.97	0.27	14.1	1.2	0.275
23	UNKNOWN	41.08	0.08	6.8	0.4	0.081
Total			100.00	574.1	442.6	100.000


1-(Pyridin-2-yl)-3-(2-furanylmethyl)guanidine hydrochloride (5k)

Chromatogram :

ssmmmm6-2-furanylguanidine.HCl_channel1

System : HPLC-PDA
Method : Gradient
User : Daniel

Acquired : 11/10/2011 15:23:39
Processed : 11/10/2011 16:11:09
Printed : 11/10/2011 16:26:48



Peak results :

Index	Name	Time [Min]	Quantity [% Area]	Height [mAU]	Area [mAU Min]	Area %
1	UNKNOWN	13.78	0.56	1.8	1.5	0.588
2	UNKNOWN	14.49	0.22	1.4	0.7	0.288
3	UNKNOWN	15.84	0.11	0.8	0.3	0.109
4	UNKNOWN	17.44	0.15	2.7	0.4	0.150
5	UNKNOWN	22.21	0.32	0.9	0.8	0.323
6	UNKNOWN	24.81	95.51	374.2	344.7	95.511
7	UNKNOWN	26.88	1.71	23.1	4.4	1.714
8	UNKNOWN	26.99	0.35	8.1	0.9	0.348
9	UNKNOWN	28.08	0.03	0.8	0.1	0.007
10	UNKNOWN	28.29	0.00	0.2	0.0	0.004
11	UNKNOWN	28.83	0.01	0.4	0.0	0.008
12	UNKNOWN	28.73	0.01	0.3	0.0	0.008
13	UNKNOWN	28.93	0.03	0.4	0.1	0.026
14	UNKNOWN	29.04	0.03	0.9	0.1	0.027
15	UNKNOWN	29.18	0.02	0.7	0.0	0.018
16	UNKNOWN	29.25	0.01	0.3	0.0	0.006
17	UNKNOWN	29.45	0.01	2.4	0.0	0.008
18	UNKNOWN	29.58	0.01	0.4	0.0	0.008
19	UNKNOWN	29.85	0.01	0.5	0.0	0.011
20	UNKNOWN	29.78	0.01	0.5	0.0	0.013
21	UNKNOWN	29.87	0.02	0.6	0.0	0.015
22	UNKNOWN	29.98	0.01	0.5	0.0	0.011
23	UNKNOWN	30.07	0.01	0.4	0.0	0.010
24	UNKNOWN	30.27	0.01	0.5	0.0	0.010
25	UNKNOWN	30.38	0.08	1.8	0.2	0.083
26	UNKNOWN	30.55	0.02	0.7	0.0	0.019
27	UNKNOWN	30.84	0.02	0.6	0.0	0.017
28	UNKNOWN	30.78	0.02	0.7	0.0	0.018
29	UNKNOWN	30.83	0.02	0.7	0.0	0.018
30	UNKNOWN	30.93	0.01	0.5	0.0	0.010
31	UNKNOWN	31.03	0.01	0.5	0.0	0.011


Page

1-(5-Bromopyridin-2-yl)guanidine hydrochloride (6c)

Chromatogram : bki95-Br-Gua.HCl_channel1

System : HPLC-PDA
Method : Gradient1
User : Daniel

Acquired : 08/02/2011 13:45:26
Processed : 08/02/2011 14:32:55
Printed : 08/02/2011 15:00:47



Peak results :


Index	Name	Time [Min]	Quantity [% Area]	Height [mAU]	Area [mAU.Min]	Area % [%]
1	UNKNOWN	23.40	0.44	39.6	7.7	0.440
2	UNKNOWN	23.88	99.08	2324.8	1738.9	99.079
3	UNKNOWN	29.80	0.07	7.0	1.2	0.071
4	UNKNOWN	32.39	0.14	12.1	2.5	0.141
5	UNKNOWN	34.11	0.02	3.8	0.4	0.021
6	UNKNOWN	34.89	0.02	2.9	0.3	0.015
7	UNKNOWN	35.55	0.07	6.7	1.3	0.073
8	UNKNOWN	35.77	0.04	5.5	0.7	0.039
9	UNKNOWN	35.96	0.03	3.4	0.5	0.027
10	UNKNOWN	36.76	0.01	3.3	0.3	0.015
11	UNKNOWN	37.00	0.04	4.4	0.8	0.044
12	UNKNOWN	37.63	0.03	3.6	0.5	0.026
13	UNKNOWN	38.20	0.01	1.6	0.2	0.010
Total			100.00	2418.5	1755.1	100.000

1-(5-Chloropyridin-2-yl)guanidine hydrochloride (7c)

Chromatogram : bki86-Cl-Gua.HCl_channel1

System : HPLC-PDA
Method : Gradient1
User : Daniel

Acquired : 08/02/2011 12:32:54
Processed : 08/02/2011 13:20:22
Printed : 08/02/2011 13:46:44



Peak results :


Index	Name	Time [Min]	Quantity [% Area]	Height [mAU]	Area [mAU·min]	Area [%]
1	UNKNOWN	22.09	0.38	48.0	7.8	0.380
2	UNKNOWN	22.68	99.01	2036.4	2032.4	99.014
3	UNKNOWN	27.97	0.33	28.6	6.6	0.330
4	UNKNOWN	29.93	0.05	5.7	1.0	0.047
5	UNKNOWN	32.51	0.10	12.1	2.0	0.098
6	UNKNOWN	34.49	0.02	3.5	0.5	0.023
7	UNKNOWN	34.51	0.02	3.9	0.4	0.018
8	UNKNOWN	34.73	0.00	1.2	0.1	0.003
9	UNKNOWN	34.96	0.01	1.6	0.2	0.009
10	UNKNOWN	35.32	0.02	4.0	0.5	0.023
11	UNKNOWN	36.75	0.01	1.4	0.1	0.005
12	UNKNOWN	38.57	0.04	3.6	0.9	0.044
13	UNKNOWN	39.07	0.01	1.1	0.1	0.006
Total			100.00	2151.3	2052.7	100.000

1-(5-Chloropyridin-2'-yl)-2-iminoimidazolidine hydrochloride (7d)

Chromatogram :
bki305-2-im-5-Cl-pyr.HCl_channel1

System : HPLC-PDA
Method : Gradient1
User : Daniel

Acquired : 11/08/2011 12:01:26
Processed : 11/08/2011 14:26:07
Printed : 11/08/2011 14:27:17



Peak results :


Index	Name	Time [Min]	Quantity [% Area]	Height [mAU]	Area [mAU.Min]	Area % [%]
1	UNKNOWN	2.04	0.69	47.6	8.2	0.689
2	UNKNOWN	2.36	98.74	2740.3	1176.6	98.743
3	UNKNOWN	23.43	0.24	12.2	2.8	0.237
4	UNKNOWN	26.49	0.33	13.7	3.9	0.331
Total			100.00	2813.7	1191.5	100.000

1-(5-Chloropyridin-2-yl)-3-(propyl)guanidine hydrochloride (7l)

Chromatogram : bki161-Cl-Gua-nPr.HCl_channel1

System : HPLC-PDA
Method : Gradient1
User : Daniel

Acquired : 08/02/2011 14:59:26
Processed : 08/02/2011 15:46:55
Printed : 08/02/2011 15:52:00



Peak results :


Index	Name	Time [Min]	Quantity [% Area]	Height [mAU]	Area [mAU.Min]	Area % [%]
1	UNKNOWN	23.47	0.35	49.7	13.2	0.351
2	UNKNOWN	24.53	0.15	29.8	5.5	0.147
3	UNKNOWN	26.40	99.31	2700.8	3728.6	99.314
4	UNKNOWN	29.77	0.03	7.0	1.0	0.027
5	UNKNOWN	32.41	0.07	14.1	2.5	0.066
6	UNKNOWN	33.36	0.00	2.7	0.2	0.005
7	UNKNOWN	34.59	0.03	5.8	1.0	0.026
8	UNKNOWN	34.81	0.01	3.1	0.5	0.014
9	UNKNOWN	37.13	0.01	3.9	0.5	0.014
10	UNKNOWN	37.69	0.02	4.1	0.8	0.020
11	UNKNOWN	38.79	0.00	1.5	0.1	0.003
12	UNKNOWN	40.92	0.01	2.7	0.4	0.011
Total			100.00	2825.4	3754.3	100.000

1-(5-Methylpyridin-2-yl)guanidine hydrochloride (8c)

Chromatogram : bki83-2_channel1

System : HPLC-PDA
Method : Gradient1
User : Daniel

Acquired : 31/01/2011 18:45:14
Processed : 31/01/2011 17:32:43
Printed : 03/02/2011 15:00:18



Peak results :

Index	Name	Time (Min)	Quantity (% Area)	Height (mAU)	Area (mAU Min)	Area % (%)
1	UNKNOWN	15.91	0.09	5.4	1.0	0.085
2	UNKNOWN	18.15	0.04	3.4	0.5	0.041
3	UNKNOWN	20.20	0.01	1.0	0.1	0.008
4	UNKNOWN	20.89	0.03	3.8	0.5	0.028
5	UNKNOWN	21.57	98.29	1170.8	1207.7	98.294
6	UNKNOWN	22.39	0.02	1.1	0.2	0.020
7	UNKNOWN	30.04	1.05	52.9	13.0	1.054
8	UNKNOWN	31.80	0.03	2.4	0.3	0.025
9	UNKNOWN	32.35	0.05	0.7	0.0	0.005
10	UNKNOWN	32.71	0.05	0.7	0.0	0.005
11	UNKNOWN	33.09	0.05	0.8	0.0	0.005
12	UNKNOWN	33.07	0.05	0.8	0.0	0.005
13	UNKNOWN	33.48	0.01	1.8	0.1	0.012
14	UNKNOWN	33.85	0.02	1.5	0.2	0.015
15	UNKNOWN	34.40	0.02	2.9	0.3	0.025
16	UNKNOWN	34.56	0.02	3.1	0.3	0.022
17	UNKNOWN	34.88	0.04	4.2	0.5	0.039
18	UNKNOWN	34.85	0.01	1.3	0.1	0.008
19	UNKNOWN	35.01	0.01	1.4	0.1	0.011
20	UNKNOWN	35.85	0.06	5.0	1.0	0.078
21	UNKNOWN	35.80	0.03	3.1	0.3	0.028
22	UNKNOWN	35.95	0.04	3.8	0.5	0.039
23	UNKNOWN	36.27	0.02	2.8	0.3	0.029
24	UNKNOWN	36.48	0.01	1.7	0.2	0.014
25	UNKNOWN	37.12	0.01	1.2	0.1	0.008
26	UNKNOWN	37.52	0.02	1.8	0.2	0.016
27	UNKNOWN	37.71	0.05	0.7	0.0	0.005
28	UNKNOWN	38.17	0.03	1.7	0.4	0.038
29	UNKNOWN	39.57	0.01	1.2	0.1	0.009
30	UNKNOWN	40.37	0.02	1.9	0.3	0.021
31	UNKNOWN	41.29	0.02	1.8	0.3	0.023


1-(5-Methylpyridin-2'-yl)-2-iminoimidazolidine hydrochloride (8d)

Chromatogram :

bki284-2-im-5-Me-py.HCl_channel1

System : HPLC-PDA
Method : Gradient1
User : Daniel

Acquired : 25/07/2011 11:27:34
Processed : 25/07/2011 12:15:03
Printed : 25/07/2011 12:21:47



Peak results :


Index	Name	Time [Min]	Quantity (% Area)	Height (mAU)	Area (mAU·Min)	Area %
1	UNKNOWN	17.93	0.01	0.9	0.1	0.010
2	UNKNOWN	19.79	0.01	0.7	0.0	0.007
3	UNKNOWN	20.01	0.01	0.6	0.0	0.006
4	UNKNOWN	20.24	0.32	10.4	2.1	0.323
5	UNKNOWN	20.89	0.01	0.7	0.0	0.007
6	UNKNOWN	20.95	0.45	13.0	3.0	0.451
7	UNKNOWN	21.32	0.02	1.6	0.1	0.022
8	UNKNOWN	21.75	0.08	2.2	0.5	0.075
9	UNKNOWN	22.31	95.37	975.4	934.1	95.371
10	UNKNOWN	23.87	0.05	2.7	0.4	0.054
11	UNKNOWN	24.31	0.02	1.5	0.1	0.021
12	UNKNOWN	24.52	0.14	4.6	0.9	0.139
13	UNKNOWN	26.88	1.81	59.2	11.9	1.807
14	UNKNOWN	29.25	0.10	4.4	0.6	0.096
15	UNKNOWN	29.53	0.03	1.9	0.2	0.026
16	UNKNOWN	30.28	0.02	1.1	0.2	0.023
17	UNKNOWN	30.64	0.08	3.4	0.5	0.081
18	UNKNOWN	32.01	0.36	11.6	2.3	0.357
19	UNKNOWN	32.45	0.10	4.2	0.8	0.095
20	UNKNOWN	32.89	0.03	1.4	0.2	0.028
Total			100.00	1101.4	858.0	100.000

1-(5-Methylpyridin-2-yl)-3-(phenyl)guanidine hydrochloride (8i)

Chromatogram :
ssmmm11-5-Me-py-gua-ph.HCl_channel1

System : HPLC-PDA
Method : Gradient1
User : Daniel

Acquired : 08/11/2011 11:55:22
Processed : 08/11/2011 12:42:51
Printed : 08/11/2011 12:48:40



Peak results :

Index	Name	Time [Min]	Quantity	Height	Area [mAU.Min]	Area % [%]
			[% Area]	[mAU]		
1	UNKNOWN	22.20	0.04	3.5	0.4	0.035
2	UNKNOWN	23.29	0.06	3.9	0.6	0.056
3	UNKNOWN	25.51	0.10	7.8	1.0	0.100
4	UNKNOWN	26.15	0.01	1.1	0.1	0.009
5	UNKNOWN	26.68	0.80	52.5	8.3	0.804
6	UNKNOWN	27.09	98.85	1829.3	1018.6	98.846
7	UNKNOWN	28.89	0.15	7.1	1.5	0.150
Total			100.00	1905.2	1030.5	100.000


1-(5-Methylpyridin-2-yl)-3-(2-hydroxyethyl)guanidine hydrochloride (8j)

Chromatogram :

ssmmmm8-5-Me-py-Gua-hydroxyethyl.HCl channel

System : HPLC-PDA
Method : Gradient1
User : Daniel

Acquired : 07/11/2011 14:53:06
Processed : 07/11/2011 15:40:36
Printed : 07/11/2011 16:10:29



Peak results :

Index	Name	Time [Min]	Quantity [% Area]	Height [mAU]	Area [mAU.Min]	Area [%]
1	UNKNOWN	9.37	0.11	4.2	1.3	0.113
2	UNKNOWN	17.28	0.05	4.3	0.6	0.054
3	UNKNOWN	21.83	98.20	1113.9	1106.9	98.197
4	UNKNOWN	25.68	1.00	48.0	11.3	1.003
5	UNKNOWN	27.01	0.26	13.6	2.9	0.256
6	UNKNOWN	27.36	0.38	17.2	4.2	0.376
Total			100.00	1201.3	1127.2	100.000


1-(5-Methylpyridin-2-yl)-3-(2-furanylmethyl)guanidine hydrochloride (8k)

Chromatogram :

ssmmm5-5-Me-2-furanylguanidine.HCl_channel1

System : HPLC-PDA
Method : Gradient1
User : Daniel

Acquired : 11/10/2011 14:25:21
Processed : 11/10/2011 15:12:51
Printed : 11/10/2011 15:28:51



Peak results :


Index	Name	Time (Min)	Quantity (% Area)	Height (mAU)	Area (mAU·Min)	Area % (%)
1	UNKNOWN	19.52	0.01	0.4	0.0	0.014
2	UNKNOWN	19.78	0.01	0.3	0.0	0.009
3	UNKNOWN	20.21	0.02	0.4	0.1	0.024
4	UNKNOWN	20.45	0.02	0.6	0.0	0.021
5	UNKNOWN	20.87	0.03	0.5	0.1	0.029
6	UNKNOWN	21.07	0.07	0.7	0.2	0.066
7	UNKNOWN	22.03	0.41	1.3	0.6	0.408
8	UNKNOWN	22.79	0.20	0.8	0.4	0.187
9	UNKNOWN	25.28	0.01	0.3	0.0	0.011
10	UNKNOWN	25.13	0.01	0.3	0.0	0.011
11	UNKNOWN	25.85	0.05	0.8	0.1	0.045
12	UNKNOWN	26.05	0.01	0.4	0.0	0.012
13	UNKNOWN	26.43	0.01	0.4	0.0	0.012
14	UNKNOWN	26.96	98.38	425.7	222.6	98.378
15	UNKNOWN	29.13	0.05	1.7	0.2	0.083
16	UNKNOWN	29.37	0.02	0.8	0.0	0.020
17	UNKNOWN	29.98	0.02	0.6	0.0	0.017
18	UNKNOWN	30.47	0.14	2.3	0.3	0.143
19	UNKNOWN	30.83	0.03	0.4	0.0	0.008
20	UNKNOWN	31.39	0.03	0.6	0.0	0.012
21	UNKNOWN	31.49	0.01	0.3	0.0	0.006
22	UNKNOWN	31.57	0.01	0.3	0.0	0.006
23	UNKNOWN	31.87	0.01	0.4	0.0	0.008
24	UNKNOWN	31.78	0.01	0.4	0.0	0.008
25	UNKNOWN	32.31	0.01	0.3	0.0	0.007
26	UNKNOWN	32.40	0.02	0.6	0.0	0.017
27	UNKNOWN	32.59	0.16	1.8	0.2	0.100
28	UNKNOWN	32.88	0.04	1.4	0.1	0.044
29	UNKNOWN	32.77	0.02	0.7	0.0	0.020
30	UNKNOWN	32.88	0.01	0.3	0.0	0.008
31	UNKNOWN	33.16	0.05	1.1	0.1	0.051

1-(5-Methylpyridin-2-yl)-3-(propyl)guanidine hydrochloride (8l)

Chromatogram : bki161-Me-Gua-nPr.HCl_channel1

System : HPLC-PDA
Method: Gradient1
User : Daniel

Acquired : 08/02/2011 15:50:31
Processed : 08/02/2011 16:36:00
Printed : 14/02/2011 13:08:45



Peak results :


Index	Name	Time [Min]	Quantity [% Area]	Height [mAU]	Area [mAU Min]	Area % [%]
1	UNKNOWN	8.44	0.01	3.8	0.3	0.006
2	UNKNOWN	9.33	0.02	9.3	1.0	0.019
3	UNKNOWN	9.91	0.00	3.0	0.2	0.004
4	UNKNOWN	10.23	0.00	2.0	0.2	0.004
5	UNKNOWN	10.59	0.01	5.5	0.5	0.009
6	UNKNOWN	10.77	0.00	2.5	0.1	0.003
7	UNKNOWN	19.51	0.05	9.1	2.6	0.047
8	UNKNOWN	20.64	0.05	16.8	2.5	0.046
9	UNKNOWN	21.81	0.38	69.7	20.9	0.383
10	UNKNOWN	22.76	0.11	36.1	6.0	0.110
11	UNKNOWN	23.29	0.53	96.4	28.7	0.527
12	UNKNOWN	23.89	0.11	30.3	6.0	0.110
13	UNKNOWN	24.57	96.87	2641.7	5271.8	96.873
14	UNKNOWN	27.80	0.61	105.7	33.1	0.009
15	UNKNOWN	29.24	0.28	73.4	15.3	0.282
16	UNKNOWN	30.11	0.03	11.9	1.7	0.031
17	UNKNOWN	30.60	0.02	7.4	1.2	0.023
18	UNKNOWN	31.49	0.64	119.4	35.1	0.645
19	UNKNOWN	32.17	0.00	1.1	0.1	0.002
20	UNKNOWN	32.35	0.02	7.7	1.0	0.019
21	UNKNOWN	33.20	0.16	36.1	8.8	0.162
22	UNKNOWN	33.76	0.04	16.0	1.9	0.036
23	UNKNOWN	34.83	0.02	7.3	1.0	0.018
24	UNKNOWN	34.95	0.01	3.2	0.4	0.007
25	UNKNOWN	36.43	0.01	3.6	0.3	0.006
26	UNKNOWN	36.56	0.01	4.2	0.7	0.013
27	UNKNOWN	36.97	0.00	1.7	0.1	0.002
28	UNKNOWN	38.15	0.01	2.9	0.3	0.005
Total			100.00	3319.7	5442.0	100.000

1-(5,6,7,8-Tetrahydroquinolin-2-yl)guanidine hydrochloride (9c)

Chromatogram : bki56-THQ-Gua.HCl_channel1

System : HPLC-PDA
 Method : Gradient1
 User : Daniel

Acquired : 08/02/2011 11:27:01
 Processed : 08/02/2011 12:14:30
 Printed : 08/02/2011 12:29:18



Peak results :


Index	Name	Time (Min)	Quantity (% Area)	Height (mAU)	Area (mAU Min)	Area % (%)
1	UNKNOWN	18.21	0.00	0.9	0.1	0.004
2	UNKNOWN	19.78	0.01	1.7	0.1	0.010
3	UNKNOWN	20.18	0.01	1.4	0.2	0.014
4	UNKNOWN	20.41	0.01	1.6	0.1	0.009
5	UNKNOWN	21.64	0.02	2.5	0.2	0.016
6	UNKNOWN	22.13	0.25	15.5	3.7	0.267
7	UNKNOWN	22.29	0.26	21.1	4.6	0.288
8	UNKNOWN	22.84	0.17	10.3	2.6	0.171
9	UNKNOWN	23.40	0.08	7.6	1.1	0.078
10	UNKNOWN	25.03	0.13	13.0	2.0	0.192
11	UNKNOWN	26.38	0.21	23.0	3.2	0.212
12	UNKNOWN	26.49	0.12	18.5	1.8	0.122
13	UNKNOWN	27.03	0.14	1530.7	1484.9	0.8145
14	UNKNOWN	29.77	0.09	8.7	1.4	0.090
15	UNKNOWN	32.17	0.95	27.2	5.4	0.395
16	UNKNOWN	33.17	0.00	0.8	0.1	0.004
17	UNKNOWN	33.65	0.00	1.1	0.1	0.004
18	UNKNOWN	33.75	0.01	2.3	0.2	0.010
19	UNKNOWN	33.93	0.01	1.9	0.2	0.014
20	UNKNOWN	35.31	0.01	2.6	0.2	0.016
21	UNKNOWN	36.53	0.01	2.0	0.2	0.015
22	UNKNOWN	36.78	0.00	0.9	0.1	0.004
23	UNKNOWN	37.05	0.01	1.8	0.2	0.012
24	UNKNOWN	37.89	0.02	2.1	0.3	0.021
25	UNKNOWN	38.00	0.01	1.4	0.1	0.008
26	UNKNOWN	38.47	0.01	1.1	0.1	0.006
Total		100.00	1867.9	1511.0	100.000	

1-(5,6,7,8-Tetrahydroquinolin-2'-yl)-2-iminoimidazolidine hydrochloride (9d)

Chromatogram : bki304-r-im1-thq.hcl_channel1

System : HPLC-PDA
Method : Gradient1
User : Daniel

Acquired : 11/08/2011 11:12:42
Processed : 11/08/2011 12:00:11
Printed : 11/08/2011 12:02:45



Peak results :


Index	Name	Time [Min]	Quantity [% Area]	Height [mAU]	Area [mAU.Min]	Area % [%]
1	UNKNOWN	20.39	0.35	18.3	6.4	0.354
2	UNKNOWN	21.07	0.27	9.9	4.8	0.267
3	UNKNOWN	21.47	0.12	8.6	2.3	0.124
4	UNKNOWN	22.03	0.96	51.8	17.5	0.963
5	UNKNOWN	22.89	0.41	28.0	7.5	0.411
6	UNKNOWN	23.69	0.09	7.6	1.6	0.085
7	UNKNOWN	26.65	96.99	1737.6	1760.6	96.992
8	UNKNOWN	29.04	0.15	10.9	2.7	0.150
9	UNKNOWN	29.40	0.04	3.2	0.7	0.036
10	UNKNOWN	29.89	0.60	27.5	10.8	0.597
11	UNKNOWN	30.52	0.01	2.2	0.2	0.013
12	UNKNOWN	31.84	0.01	1.5	0.2	0.009
Total			100.00	1907.2	1815.2	100.000

1-(5,6,7,8-Tetrahydroquinolin-2-yl)-3-(phenyl)guanidine hydrochloride (9i)

bki376b-THQ-Gua-Ph.HCl_channel1

System : HPLC-PDA
Method : Gradient1
User : Daniel

Acquired : 17/01/2012 14:42:17
Processed : 17/01/2012 16:53:15
Printed : 17/01/2012 16:53:47



Peak results :

Index	Name	Time (Min.)	Quantity (% Area)	Height (mAU)	Area (mAU Min.)	Area % (%)
1	UNKNOWN	14.57	0.02	0.5	0.1	0.023
2	UNKNOWN	15.04	0.03	0.6	0.1	0.030
3	UNKNOWN	15.75	0.10	1.4	0.2	0.100
4	UNKNOWN	16.83	0.00	1.3	0.2	0.087
5	UNKNOWN	16.98	0.13	1.2	0.3	0.134
6	UNKNOWN	18.00	0.09	1.2	0.2	0.090
7	UNKNOWN	20.15	0.35	3.1	0.8	0.352
8	UNKNOWN	20.43	0.10	1.5	0.2	0.103
9	UNKNOWN	21.64	0.06	0.8	0.1	0.052
10	UNKNOWN	22.04	0.11	1.0	0.3	0.110
11	UNKNOWN	22.72	0.27	1.6	0.5	0.272
12	UNKNOWN	22.85	0.07	1.3	0.2	0.071
13	UNKNOWN	23.03	0.10	1.5	0.2	0.090
14	UNKNOWN	23.12	0.08	1.4	0.2	0.080
15	UNKNOWN	23.51	0.11	1.0	0.3	0.113
16	UNKNOWN	25.76	0.03	0.6	0.1	0.027
17	UNKNOWN	25.81	0.04	0.6	0.1	0.044
18	UNKNOWN	26.81	0.17	1.2	0.4	0.170
19	UNKNOWN	26.85	1.02	19.0	2.3	1.018
20	UNKNOWN	27.41	0.78	7.8	1.9	0.780
21	UNKNOWN	28.52	0.01	0.4	0.1	0.016
22	UNKNOWN	30.12	0.12	2.3	0.3	0.124
23	UNKNOWN	30.78	0.06	0.8	0.1	0.063
24	UNKNOWN	31.11	95.63	384.4	250.5	95.605
25	UNKNOWN	33.89	0.45	3.2	1.0	0.455
Total		100.00	439.8	230.5	100.000	


1-(5,6,7,8-Tetrahydroquinolin-2-yl)-3-(2-hydroxyethyl)guanidine hydrochloride (9j)

Chromatogram :

ssmmm-21-thq-gua-hydroxyethyl.HCl_channel1

System : HPLC-PDA
Method : Gradient1
User : Daniel

Acquired : 17/11/2011 11:38:10
Processed : 17/11/2011 12:25:39
Printed : 17/11/2011 12:40:53



Peak results :

Index	Name	Time [Min]	Quantity % Area	Height [mAU]	Area [mAU.Min]	Area % [%]
1	UNKNOWN	22.04	0.02	1.6	0.2	0.023
2	UNKNOWN	22.57	0.03	2.7	0.3	0.034
3	UNKNOWN	22.80	0.05	3.3	0.5	0.051
4	UNKNOWN	25.05	0.01	0.9	0.1	0.010
5	UNKNOWN	25.79	0.38	22.2	3.4	0.382
6	UNKNOWN	26.00	0.29	14.2	2.5	0.290
7	UNKNOWN	26.89	96.37	967.1	845.7	96.372
8	UNKNOWN	28.69	2.62	46.4	23.0	2.625
9	UNKNOWN	30.31	0.13	7.1	1.2	0.132
10	UNKNOWN	31.64	0.02	2.0	0.2	0.023
11	UNKNOWN	32.17	0.01	0.7	0.0	0.005
12	UNKNOWN	32.56	0.00	0.6	0.0	0.004
13	UNKNOWN	33.03	0.00	0.4	0.0	0.002
14	UNKNOWN	33.12	0.00	0.6	0.0	0.004
15	UNKNOWN	33.96	0.00	0.8	0.0	0.005
16	UNKNOWN	34.43	0.00	0.6	0.0	0.003
17	UNKNOWN	36.07	0.02	1.9	0.2	0.023
18	UNKNOWN	36.15	0.01	1.0	0.1	0.011
Total			100.00	1074.1	877.5	100.000

1-(5,6,7,8-Tetrahydroquinolin-2-yl)-3-(2-furanylmethyl)guanidine hydrochloride (9k)

Chromatogram :

ssmmm23-THQ-gua-furanyl.HCl_23_11_2011

12em49PL35.D

Method : GradientT


User : Daniel

Acquired : 23/11/2011 12:50:24

Processed : 23/11/2011 13:37:53

Printed : 23/11/2011 14:34:01

ssmmm23-THQ-gua-furanyl.HCl_23_11_2011 12_49_35.DATA - Prostar 335 Absorbance Analog Channel 1 LC0908M822



Peak results :

Index	Name	Time [Min]	Quantity [% Area]	Height [mAU]	Area [mAU.Min]	Area [%]
1	UNKNOWN	26.88	0.94	56.0	10.4	0.938
2	UNKNOWN	28.20	0.07	5.9	0.8	0.072
3	UNKNOWN	29.59	0.01	1.0	0.1	0.007
4	UNKNOWN	29.92	0.19	24.0	2.2	0.195
5	UNKNOWN	29.96	0.19	21.3	2.2	0.194
6	UNKNOWN	30.09	0.07	8.7	0.8	0.068
7	UNKNOWN	30.64	98.42	1420.1	1093.1	98.423
8	UNKNOWN	32.13	0.06	11.2	0.7	0.063
9	UNKNOWN	32.25	0.02	4.1	0.3	0.024
10	UNKNOWN	32.36	0.01	3.3	0.2	0.014
Total			100.00	1555.5	1110.6	100.000


1-[5-(Ethylamino)pyridin-2-yl]guanidine hydrochloride (10c)

Chromatogram :

bki448-5-NHEt-2-Gua-py.HCl_channel1

System : HPLC-PDA
Method : Gradient1
User : Daniel

Acquired : 25/04/2012 11:25:11
Processed : 25/04/2012 12:18:38
Printed : 25/04/2012 12:19:04



Peak results :


Index	Name	Time [Min]	Quantity [% Area]	Height [mAU]	Area [mAU.Min]	Area % [%]
1	UNKNOWN	3.88	99.50	3053.5	2282.1	99.499
2	UNKNOWN	14.35	0.41	40.4	9.4	0.411
3	UNKNOWN	17.83	0.07	10.5	1.6	0.071
4	UNKNOWN	23.89	0.02	3.8	0.4	0.019
Total			100.00	3108.2	2293.6	100.000

1-[5-(Ethylamino)pyridin-2'-yl]2-iminoimidazolidine hydrochloride (10d)

Chromatogram :
bki449-5NHEt-2-Imi-py.HCl_channel1

System : HPLC-PDA
Method : Gradient1
User : Daniel

Acquired : 25/04/2012 12:15:51
Processed : 25/04/2012 13:03:19
Printed : 25/04/2012 14:08:57



Peak results :


Index	Name	Time [Min]	Quantity [% Area]	Height [mAU]	Area	
					[mAU.Min]	Area % [%]
1	UNKNOWN	5.07	100.00	1543.4	1705.7	100.000
Total			100.00	1543.4	1705.7	100.000

1-(Pyridin-3-yl)guanidine hydrochloride (11c)

Chromatogram : bki21-3-Gua-Pyr.HCl_channel5

System : HPLC-PDA
Method : NOT DEFINED
User : Daniel

Acquired : 14/02/2011 13:53:21
Processed : 14/02/2011 14:59:17
Printed : 14/02/2011 14:59:48



Peak results :


Index	Name	Time [Min]	Quantity [% Area]	Height [mAU]	Area [mAU.Min]	Area % [%]
1	UNKNOWN	1.58	0.28	57.0	4.4	0.283
2	UNKNOWN	1.77	0.26	45.1	4.1	0.261
3	UNKNOWN	2.19	99.15	2785.0	1545.5	99.152
4	UNKNOWN	23.37	0.02	3.0	0.4	0.025
5	UNKNOWN	25.66	0.20	15.2	3.1	0.202
6	UNKNOWN	27.72	0.02	1.6	0.3	0.017
7	UNKNOWN	28.20	0.01	1.1	0.1	0.008
8	UNKNOWN	29.60	0.04	3.7	0.6	0.036
9	UNKNOWN	32.85	0.01	1.1	0.1	0.008
10	UNKNOWN	36.36	0.00	0.8	0.1	0.004
Total			100.00	2914.5	1558.7	100.000

1-(Pyridin-3'-yl)-2-iminoimidazolidine hydrochloride (11d)

Chromatogram : bki332-3-imy.HCl_channel1

System : HPLC-PDA
Method : Gradient1
User : Daniel

Acquired : 15/09/2011 11:38:35
Processed : 15/09/2011 12:26:04
Printed : 15/09/2011 12:31:54



Peak results :

Index	Name	Time [Min]	Quantity [% Area]	Height [mAU]	Area [mAU·Min]	Area % [%]
1	UNKNOWN	4.00	99.23	2714.2	2684.0	99.229
2	UNKNOWN	16.91	0.04	5.7	1.1	0.042
3	UNKNOWN	18.92	0.13	17.9	3.5	0.129
4	UNKNOWN	20.97	0.17	20.8	4.5	0.166
5	UNKNOWN	24.27	0.02	3.8	0.4	0.017
6	UNKNOWN	27.25	0.33	36.6	9.1	0.335
7	UNKNOWN	28.57	0.04	5.9	1.0	0.035
8	UNKNOWN	31.69	0.03	4.3	0.9	0.032
9	UNKNOWN	33.09	0.01	3.1	0.4	0.015
Total			100.00	2612.2	2704.9	100.000

1-(6-Chloropyridin-3-yl)guanidine hydrochloride (12c)


Chromatogram :

bki235-3-Gua-6-Cl-Py.HCl-Buffered-Injection_cha

Sample 1
HPLC-PDA
Method : Gradient1
User : Daniel

Acquired : 06/05/2011 11:58:11
Processed : 06/05/2011 12:53:53
Printed : 06/05/2011 12:54:36

bki235-3-Gua-6-Cl-Py.HCl-Buffered-Injection.DATA - Prostar 335 Absorbance Analog Channel 1 LC0908M822



Peak results :

Index	Name	Time [Min]	Quantity [% Area]	Height [mAU]	Area [mAU·Min]	Area [%]
1	UNKNOWN	7.43	96.03	926.2	1226.8	96.034
10	UNKNOWN	19.64	3.88	221.2	49.6	3.881
2	UNKNOWN	24.39	0.01	1.4	0.1	0.012
3	UNKNOWN	26.57	0.01	1.5	0.2	0.014
4	UNKNOWN	27.51	0.01	1.1	0.1	0.009
5	UNKNOWN	32.60	0.01	1.1	0.1	0.010
6	UNKNOWN	34.20	0.02	2.0	0.2	0.017
7	UNKNOWN	36.05	0.00	0.7	0.0	0.003
8	UNKNOWN	36.13	0.00	0.6	0.0	0.003
9	UNKNOWN	38.72	0.02	1.5	0.2	0.017
Total		100.00	1157.2	1277.4	100.000	


1-(6-Methylpyridin-3-yl)guanidine hydrochloride (13c)

Chromatogram :

bki230-3-Gua-6-Me-Py.HCl-Buffered-Injection_ch

channel 1
Method : LC-PDA
Method : Gradient1
User : Daniel

Acquired : 06/05/2011 11:03:28
Processed : 06/05/2011 12:01:11
Printed : 06/05/2011 12:02:27




Peak results :

Index	Name	Time [Min]	Quantity [% Area]	Height [mAU]	Area [mAU.Min]	Area [%]
1	UNKNOWN	3.16	99.74	2322.5	683.4	99.743
2	UNKNOWN	26.75	0.04	2.5	0.3	0.039
3	UNKNOWN	31.51	0.13	7.8	0.9	0.129
4	UNKNOWN	32.68	0.03	2.0	0.2	0.032
5	UNKNOWN	34.08	0.06	3.2	0.4	0.057
Total			100.00	2337.9	685.2	100.000

1-(5,6,7,8-Tetrahydroquinolin-3-yl)guanidine hydrochloride (14c)

Chromatogram : bki321-3-gua-THQ.HCl_channel1

System : HPLC-PDA
 Method : Gradient1
 User : Daniel
 Acquired : 15/09/2011 15:05:50
 Proceeded : 15/09/2011 16:27:17
 Printed : 15/09/2011 16:27:43



Peak results :

Index	Name	Time [Min]	Quantity [% Area]	Height [mAU]	Area [mAU·Min]	Area %
148	UNKNOWN	10.11	98.39	421.4	1231.5	98.394
1	UNKNOWN	16.78	0.01	0.7	0.1	0.006
2	UNKNOWN	17.43	0.08	3.8	1.0	0.077
3	UNKNOWN	18.07	0.50	11.0	8.4	0.498
4	UNKNOWN	19.45	0.02	1.4	0.2	0.018
5	UNKNOWN	19.77	0.13	7.2	1.8	0.129
6	UNKNOWN	21.01	0.00	0.5	0.1	0.005
7	UNKNOWN	21.19	0.01	0.6	0.1	0.007
8	UNKNOWN	21.39	0.00	0.4	0.1	0.004
9	UNKNOWN	21.77	0.02	1.4	0.3	0.024
10	UNKNOWN	21.93	0.01	0.7	0.1	0.006
11	UNKNOWN	21.99	0.01	0.8	0.2	0.012
12	UNKNOWN	22.49	0.01	0.7	0.1	0.005
13	UNKNOWN	23.65	0.11	5.7	1.4	0.107
14	UNKNOWN	25.65	0.10	2.9	1.5	0.103
15	UNKNOWN	27.13	1.81	43.0	20.8	1.814
16	UNKNOWN	28.21	0.01	0.9	0.1	0.010
17	UNKNOWN	28.45	0.02	2.1	0.2	0.015
18	UNKNOWN	28.56	0.02	2.2	0.2	0.019
19	UNKNOWN	28.65	0.01	1.9	0.2	0.014
20	UNKNOWN	28.78	0.00	0.8	0.1	0.008
21	UNKNOWN	28.99	0.04	3.6	0.8	0.045
22	UNKNOWN	29.21	0.00	0.5	0.0	0.004
23	UNKNOWN	29.51	0.02	2.2	0.3	0.022
24	UNKNOWN	29.71	0.00	0.4	0.0	0.001
25	UNKNOWN	29.81	0.01	1.4	0.1	0.008
26	UNKNOWN	29.89	0.00	0.9	0.1	0.005
27	UNKNOWN	30.00	0.00	0.8	0.0	0.003
28	UNKNOWN	30.19	0.01	0.8	0.1	0.007
29	UNKNOWN	30.40	0.03	2.9	0.3	0.026
30	UNKNOWN	30.49	0.03	3.7	0.3	0.027


Peak

1-(5,6,7,8-Tetrahydroquinolin-3'-yl)-2-iminoimidazolidine hydrochloride (14d)

Chromatogram : bki320-3-im1-THQ.HCl_channel1

System : HPLC-PDA
 Method : Gradient1
 User : Daniel

Acquired : 15/09/2011 13:49:17
 Processed : 15/09/2011 15:11:10
 Printed : 15/09/2011 15:11:27



Peak results :

Index	Name	Time Min	Quantity %	Height mAU	Area mAU.Min	Area %
1	UNKNOWN	5.32	0.03	1.2	0.2	0.028
2	UNKNOWN	17.20	06.06	700.7	412.5	99.084
3	UNKNOWN	18.89	0.02	1.2	0.2	0.024
4	UNKNOWN	19.51	0.08	1.9	0.5	0.083
5	UNKNOWN	20.79	0.01	0.7	0.1	0.013
6	UNKNOWN	20.72	0.73	8.1	4.7	0.720
81	UNKNOWN	21.23	1.85	31.9	11.8	1.853
7	UNKNOWN	23.27	0.09	0.7	0.1	0.017
5	UNKNOWN	26.68	0.10	2.2	0.7	0.104
9	UNKNOWN	29.01	0.02	1.1	0.1	0.017
10	UNKNOWN	29.23	0.01	0.7	0.0	0.007
11	UNKNOWN	29.52	0.03	1.4	0.2	0.027
12	UNKNOWN	29.83	0.02	1.4	0.1	0.021
13	UNKNOWN	29.93	0.01	0.7	0.0	0.006
14	UNKNOWN	30.04	0.01	0.8	0.1	0.009
15	UNKNOWN	30.12	0.01	0.7	0.0	0.007
16	UNKNOWN	30.51	0.10	3.2	0.6	0.097
17	UNKNOWN	30.81	0.03	2.1	0.2	0.026
18	UNKNOWN	30.71	0.02	1.8	0.1	0.018
19	UNKNOWN	30.89	0.04	1.8	0.3	0.042
20	UNKNOWN	31.05	0.01	1.0	0.1	0.009
21	UNKNOWN	31.27	0.00	0.5	0.0	0.003
22	UNKNOWN	31.45	0.14	5.1	0.9	0.144
23	UNKNOWN	31.84	0.01	1.0	0.1	0.010
24	UNKNOWN	31.84	0.01	0.7	0.0	0.005
25	UNKNOWN	32.01	0.01	0.9	0.0	0.008
26	UNKNOWN	32.11	0.01	0.8	0.0	0.006
27	UNKNOWN	32.39	0.00	0.7	0.0	0.005
28	UNKNOWN	32.48	0.00	0.6	0.0	0.004
29	UNKNOWN	32.57	0.01	0.7	0.0	0.006
30	UNKNOWN	32.87	0.00	0.5	0.0	0.004


1-[6-(*N*-ethylamino)pyridin-3-yl]guanidine hydrochloride (15c)

Chromatogram :

bki266-3-Gua-6-NHEtpy.HCl_channel1

System : HPLC-PDA
Method : Gradient1
User : Daniel

Acquired : 06/07/2011 16:23:43
Processed : 06/07/2011 17:29:39
Printed : 06/07/2011 17:32:11



Peak results :


Index	Name	Time [Min]	Quantity [% Area]	Height [mAU]	Area [mAU.Min]	Area % [%]
1	UNKNOWN	1.99	0.02	3.2	0.2	0.023
2	UNKNOWN	2.19	0.70	77.2	7.1	0.701
3	UNKNOWN	2.41	95.27	2905.0	976.3	95.266
4	UNKNOWN	3.45	0.35	20.2	3.5	0.348
5	UNKNOWN	4.92	0.13	6.8	1.4	0.134
6	UNKNOWN	5.39	1.41	49.2	14.3	1.405
7	UNKNOWN	14.69	0.38	8.5	3.8	0.378
8	UNKNOWN	14.76	0.15	5.5	1.5	0.147
9	UNKNOWN	22.51	0.05	4.0	0.5	0.048
10	UNKNOWN	26.64	0.48	30.5	4.9	0.480
11	UNKNOWN	31.72	0.07	6.3	0.7	0.069
Total			100.00	3117.4	1014.2	100.000

1-(6-(Ethylamino)pyridin-3'-yl)-2-iminoimidazolidine hydrochloride (15d)

Chromatogram :
bki310-3-im1-6-NHEt-py.2HCl_channel1

System : HPLC-PDA
Method : Gradient1
User : Daniel

Acquired : 15/09/2011 12:37:37
Processed : 15/09/2011 13:50:29
Printed : 15/09/2011 13:51:10



Peak results :


Index	Name	Time [Min]	Quantity [% Area]	Height [mAU]	Area [mAU.Min]	Area % [%]
1	UNKNOWN	3.21	97.88	2494.2	12886.6	97.877
2	UNKNOWN	4.91	0.10	8.2	1.4	0.103
3	UNKNOWN	7.47	1.41	41.7	18.5	1.411
4	UNKNOWN	27.29	0.58	24.3	7.6	0.579
5	UNKNOWN	31.45	0.02	2.7	0.2	0.018
6	UNKNOWN	32.84	0.01	1.4	0.2	0.013
Total			100.00	2572.4	1314.5	100.000

1-(5-Nitropyridin-2-yl)guanidine hydrochloride (17c)

Chromatogram :

bki169b-NO2-Pyr-Gua.HCl_channel1

System : HPLC-PDA
 Method : Gradient1
 User : Daniel
 Acquired : 14/02/2011 13:00:41
 Processed : 14/02/2011 13:48:10
 Printed : 14/02/2011 13:54:08



Peak results :


Index	Name	Time (Min)	Quantity (% Area)	Height (mAU)	Area (mAU.Min)	Area % (%)
1	UNKNOWN	3.81	0.01	0.3	0.0	0.006
2	UNKNOWN	4.52	0.01	0.4	0.0	0.011
3	UNKNOWN	4.97	0.02	0.7	0.1	0.020
4	UNKNOWN	5.41	0.03	0.8	0.1	0.035
5	UNKNOWN	5.89	0.07	1.6	0.3	0.073
6	UNKNOWN	8.00	0.03	0.8	0.1	0.031
7	UNKNOWN	8.43	0.03	0.8	0.1	0.032
8	UNKNOWN	7.04	0.06	1.9	0.2	0.056
9	UNKNOWN	7.40	0.02	0.8	0.1	0.024
10	UNKNOWN	8.23	0.01	0.6	0.0	0.011
11	UNKNOWN	9.31	0.04	1.0	0.2	0.037
12	UNKNOWN	10.03	0.01	0.6	0.1	0.015
13	UNKNOWN	10.85	0.03	0.9	0.1	0.030
14	UNKNOWN	11.47	0.06	1.3	0.2	0.058
15	UNKNOWN	12.81	0.01	0.5	0.1	0.013
16	UNKNOWN	13.51	0.04	1.5	0.2	0.042
17	UNKNOWN	14.39	0.01	0.2	0.0	0.005
18	UNKNOWN	14.92	0.02	0.6	0.1	0.022
19	UNKNOWN	15.52	0.21	1.8	0.9	0.208
20	UNKNOWN	18.97	96.79	339.8	405.8	96.792
21	UNKNOWN	20.92	0.01	0.4	0.0	0.004
22	UNKNOWN	21.31	0.01	0.5	0.0	0.006
23	UNKNOWN	21.53	0.01	0.3	0.1	0.014
24	UNKNOWN	21.68	0.01	0.4	0.0	0.006
25	UNKNOWN	21.82	0.01	0.3	0.0	0.007
26	UNKNOWN	22.73	0.00	0.2	0.0	0.004
27	UNKNOWN	22.79	0.02	0.4	0.1	0.015
28	UNKNOWN	23.78	0.08	0.6	0.4	0.080
29	UNKNOWN	25.05	0.01	0.3	0.0	0.005
30	UNKNOWN	27.57	0.07	1.1	0.3	0.072
31	UNKNOWN	27.91	0.03	0.8	0.1	0.032

Print

1-(5-Aminopyridin-2-yl)guanidine hydrochloride (18c)

Chromatogram :

bki201-2-Gua-5-NH2-Py.HCl-Buffered-Injection_c
Channel 1-PDA
Method : Gradient
User : Daniel
Acquired : 06/05/2011 18:13:34
Processed : 06/05/2011 17:01:04
Printed : 06/05/2011 17:06:09



Peak results :


Index	Name	Time (Min)	Quantity (% Area)	Height (mAU)	Area (mAU Min)	Area % (%)
1	UNKNOWN	4.84	97.44	1284.6	803.7	97.442
2	UNKNOWN	15.51	0.03	1.7	0.2	0.032
3	UNKNOWN	18.97	0.19	8.4	1.3	0.192
4	UNKNOWN	18.33	0.26	14.5	1.8	0.287
5	UNKNOWN	19.88	1.27	22.9	7.9	1.289
6	UNKNOWN	23.41	0.03	2.0	0.2	0.034
7	UNKNOWN	24.48	0.03	1.6	0.2	0.031
8	UNKNOWN	25.49	0.04	1.6	0.2	0.039
9	UNKNOWN	26.71	0.02	1.3	0.1	0.021
10	UNKNOWN	27.58	0.02	1.1	0.1	0.021
11	UNKNOWN	27.95	0.24	7.0	1.5	0.244
12	UNKNOWN	30.20	0.01	0.6	0.0	0.008
13	UNKNOWN	31.47	0.04	1.6	0.2	0.036
14	UNKNOWN	32.08	0.01	0.7	0.0	0.005
15	UNKNOWN	32.84	0.02	1.6	0.1	0.024
16	UNKNOWN	33.11	0.01	0.6	0.0	0.006
17	UNKNOWN	33.39	0.00	0.5	0.0	0.004
18	UNKNOWN	34.05	0.16	4.0	0.6	0.066
19	UNKNOWN	34.52	0.09	4.0	0.6	0.093
20	UNKNOWN	36.17	0.08	4.0	0.5	0.075
21	UNKNOWN	38.84	0.04	1.6	0.2	0.037
Total		100.00	1347.4	819.8	100.000	

N-Phenyl-1,4-dihydroquinazolin-2-amine hydrochloride (19i)

Chromatogram :
bki413-2-Am-DHQ-Ph.HCl_channel1

System : HPLC-PDA
Method : Gradient1
User : Daniel

Acquired : 15/03/2012 15:02:28
Processed : 15/03/2012 15:59:49
Printed : 15/03/2012 16:00:07



Peak results :

Index	Name	Time [Min]	Quantity [% Area]	Height [mAU]	Area [mAU.Min]	Area [%]
1	UNKNOWN	20.88	0.06	3.4	0.7	0.055
2	UNKNOWN	24.47	0.51	16.8	8.8	0.513
9	UNKNOWN	25.11	2.12	89.4	27.3	2.124
3	UNKNOWN	26.60	0.22	13.5	2.8	0.216
4	UNKNOWN	27.41	0.11	4.8	1.5	0.114
8	UNKNOWN	28.55	96.36	1962.0	1239.4	96.364
5	UNKNOWN	31.71	0.06	6.8	0.8	0.061
6	UNKNOWN	32.37	0.17	12.6	2.2	0.173
7	UNKNOWN	33.16	0.38	32.7	4.9	0.380
Total			100.00	2141.9	1286.1	100.000


N-(2-hydroxyethyl)-1,4-dihydroquinazolin-2-amine hydrochloride (19j)

Chromatogram :

bki409-2-Am-DHQ-ethoxy.HCl_channel1

System : HPLC-PDA
Method : Gradient1
User : Daniel

Acquired: 15/03/2012 11:05:20
Processed: 15/03/2012 11:58:42
Printed: 15/03/2012 11:59:03



Peak results :

Index	Name	Time (Min)	Quantity (% Area)	Height (mAU)	Area (mAU Min)	Area % (%)
1	UNKNOWN1	13.89	0.08	1.6	0.7	0.078
2	UNKNOWN1	15.39	0.08	2.9	0.7	0.085
3	UNKNOWN1	15.84	0.05	3.1	0.4	0.047
4	UNKNOWN1	15.84	0.09	8.2	0.8	0.093
5	UNKNOWN1	15.87	0.07	5.8	0.6	0.069
6	UNKNOWN1	15.99	0.07	3.5	0.6	0.074
7	UNKNOWN1	16.56	0.06	3.0	0.5	0.061
8	UNKNOWN1	17.15	0.14	4.6	1.2	0.135
9	UNKNOWN1	17.21	0.07	3.5	0.6	0.071
10	UNKNOWN1	17.56	0.04	3.9	0.3	0.040
11	UNKNOWN1	17.85	0.12	3.5	1.1	0.125
12	UNKNOWN1	19.13	0.05	1.5	0.4	0.049
28	UNKNOWN1	19.98	97.32	543.3	846.2	97.321
13	UNKNOWN1	23.77	0.08	4.1	0.7	0.077
14	UNKNOWN1	23.92	0.05	3.7	0.4	0.051
15	UNKNOWN1	24.07	0.04	3.4	0.4	0.041
16	UNKNOWN1	25.07	0.06	4.9	0.6	0.064
17	UNKNOWN1	25.20	0.03	2.5	0.3	0.031
18	UNKNOWN1	25.36	0.05	2.6	0.5	0.054
19	UNKNOWN1	26.48	1.13	50.2	56.8	1.132
20	UNKNOWN1	28.33	0.02	1.1	0.2	0.018
21	UNKNOWN1	28.57	0.02	1.5	0.2	0.021
22	UNKNOWN1	28.87	0.04	2.7	0.3	0.039
23	UNKNOWN1	29.32	0.04	2.1	0.4	0.042
24	UNKNOWN1	30.28	0.08	4.1	0.7	0.078
25	UNKNOWN1	30.88	0.03	2.2	0.3	0.031
26	UNKNOWN1	33.01	0.06	2.5	0.5	0.056
27	UNKNOWN1	33.32	0.02	1.2	0.2	0.018
Total		100.00	875.2	869.5	100.000	


N-(2-furanylmethyl)-1,4-dihydroquinazolin-2-amine hydrochloride (19k)

Chromatogram :

bki414-2-Am-DHQ-Furanyl.HCl_channel1

System : HPLC-PDA
Method : Gradient1
User : Daniel

Acquired : 15/03/2012 14:12:24
Processed : 15/03/2012 15:05:24
Printed: 15/03/2012 15:09:11



Peak results :


Index	Name	Time [Min]	Quantity [% Area]	Height [mAU]	Area [mAU Min]	Area % [%]
1	UNKNOWN	16.72	0.13	1.7	0.5	0.126
2	UNKNOWN	17.53	0.20	2.7	0.8	0.203
3	UNKNOWN	19.24	0.03	1.2	0.1	0.032
4	UNKNOWN	19.51	0.05	1.5	0.2	0.052
5	UNKNOWN	19.75	0.03	0.8	0.1	0.026
6	UNKNOWN	20.61	0.21	4.3	0.8	0.206
7	UNKNOWN	20.83	0.11	3.2	0.4	0.114
8	UNKNOWN	21.04	0.10	2.2	0.4	0.102
9	UNKNOWN	21.60	0.13	3.6	0.5	0.125
10	UNKNOWN	21.80	0.18	3.3	0.7	0.177
11	UNKNOWN	22.15	0.07	2.2	0.3	0.072
12	UNKNOWN	22.33	0.13	2.6	0.5	0.125
13	UNKNOWN	25.23	0.06	2.2	0.2	0.056
14	UNKNOWN	26.84	0.12	3.1	0.5	0.122
17	UNKNOWN	27.95	97.04	584.7	364.2	97.037
15	UNKNOWN	32.75	0.20	3.5	0.7	0.106
16	UNKNOWN	35.48	0.63	6.8	2.3	0.626
Total		100.00	550.6	373.0	100.000	

N-(*n*-Propyl)-1,4-dihydroquinazolin-2-amine hydrochloride (19l)

Chromatogram :
bki407-2-Am-DHQ-Pr.HCl_channel1

System : HPLC-PDA
Method : Gradient1
User : Daniel

Acquired : 15/03/2012 12:01:09
Processed : 15/03/2012 12:50:16
Printed : 15/03/2012 12:50:27



Peak results :


Index	Name	Time [Min]	Quantity [% Area]	Height [mAU]	Area [mAU.Min]	Area % [%]
1	UNKNOWN	20.60	0.02	4.7	0.6	0.024
2	UNKNOWN	23.73	0.09	11.2	2.1	0.080
3	UNKNOWN	24.19	0.83	81.3	19.9	0.834
4	UNKNOWN	24.67	0.07	14.5	1.7	0.072
5	UNKNOWN	24.93	0.45	65.5	10.7	0.448
6	UNKNOWN	25.28	1.37	59.7	32.8	1.373
9	UNKNOWN	26.23	96.71	2370.0	2308.6	96.708
7	UNKNOWN	30.04	0.06	9.1	1.5	0.084
8	UNKNOWN	30.81	0.39	51.4	9.3	0.388
Total		100.00	2667.4	2387.2	100.000	

N-(2-hydroxyethyl)-1,4-dihydropyrido[2,3-d]pyrimidin-2-amine hydrochloride (20j)

Chromatogram : mm426_channel1

System : HPLC-PDA
Method : Integrate later Mic1
User : Daniel

Acquired : 19/02/2014 09:37:49
Processed : 19/02/2014 10:25:18
Printed : 31/03/2014 16:21:35



Peak results :


Index	Name	Time [Min]	Quantity [% Area]	Height [mAU]	Area [mAU.Min]	Area % [%]
1	UNKNOWN	1.87	0.19	7.9	1.4	0.185
2	UNKNOWN	2.55	97.69	1325.1	726.8	97.694
3	UNKNOWN	16.33	0.08	2.8	0.6	0.077
4	UNKNOWN	16.55	0.08	4.3	0.6	0.085
5	UNKNOWN	26.58	1.96	34.1	14.6	1.959
Total			100.00	1374.2	744.0	100.000

N-(furan-2-ylmethyl)-1,4-dihydropyrido[2,3-d]pyrimidin-2-amine hydrochloride (20k)

Chromatogram : mm406 31414_channel1

System : HPLC-PDA
Method : Gradient1
User : Daniel

Acquired : 31/03/2014 13:49:16
Processed : 31/03/2014 14:36:45
Printed : 31/03/2014 16:17:58



Peak results :


Index	Name	Time [Min]	Quantity	Height	Area [mAU.Min]	Area % [%]
			[% Area]	[mAU]		
1	UNKNOWN	18.23	0.88	23.2	15.6	0.883
2	UNKNOWN	22.15	1.95	80.1	34.5	1.954
3	UNKNOWN	23.27	96.22	2029.9	1696.7	96.215
4	UNKNOWN	26.35	0.02	3.6	0.4	0.023
5	UNKNOWN	28.44	0.07	10.2	1.3	0.072
6	UNKNOWN	28.80	0.74	26.7	13.0	0.738
7	UNKNOWN	31.12	0.01	1.7	0.2	0.009
8	UNKNOWN	31.55	0.06	6.5	1.1	0.064
9	UNKNOWN	38.79	0.04	3.6	0.7	0.042
Total			100.00	2185.4	1763.4	100.000

N-(1,3-benzodioxol-5-ylmethyl)-1,4-dihdropyrido[2,3-d]pyrimidin-2-amine hydrochloride
(20m)

Chromatogram : mm477 part 2_channel1

System : HPLC-PDA
Method : Gradient1
User : Daniel

Acquired : 08/04/2014 13:29:33
Processed : 08/04/2014 14:17:03
Printed : 08/04/2014 14:18:14



Peak results :

Index	Name	Time [Min]	Quantity [% Area]	Height [mAU]	Area [mAU.Min]	Area [%]
1	UNKNOWN	21.68	0.14	8.0	1.9	0.143
2	UNKNOWN	24.40	99.81	1699.3	1331.0	99.811
3	UNKNOWN	32.53	0.02	2.1	0.3	0.019
4	UNKNOWN	40.00	0.03	11.1	0.4	0.028
Total			100.00	1720.4	1333.6	100.000

8. Preparation of membranes

Neural membranes (P2 fractions) were prepared from the PFC of human brains obtained at autopsy in the Instituto Vasco de Medicina Legal, Bilbao, Spain, in compliance with policies of research and ethical boards for postmortem brain studies at the moment of sample obtaining. Postmortem human brain samples of each subject (~ 1 g) were homogenized using a Teflon-glass grinder (10 up-and-down strokes at 1500 rpm) in 30 volumes of homogenization buffer (1 mM MgCl₂, and 5 mM Tris-HCl, pH 7.4) supplemented with 0.25 M sucrose. The crude homogenate was centrifuged for 5 min at 1000 \times g (4 °C) and the supernatant was centrifuged again for 10 min at 40000 \times g (4 °C). The resultant pellet was washed twice in 20 volumes of homogenization buffer and re-centrifuged in similar conditions. Aliquots of 1 mg protein were stored at -70 °C until assay. Protein content was measured according to the Bradford method using BSA as standard, and was similar in the different brain samples.



9. Analysis of binding data

Analysis of competition experiments to obtain the inhibition constant (K_i) were performed by nonlinear regression using the GraphPad Prism program. All experiments were analysed assuming a one-site model of radioligand binding. K_i values were normalized to pK_i values.

10. Drugs used in pharmacology experiments

[³H]RX821002 (specific activity 55 Ci/mmol) was obtained from Amersham International, U.K. [³⁵S]GTPγS (1250 Ci/mmol) was purchased from Perkin Elmer Life Sciences (Massachusetts, USA). GDP, GTP, GTPγS, RX821002 HCl, and UK14304 were purchased from Sigma (St. Louis, U.S.A.). All other chemicals were of the highest purity commercially available.

11. $[^{35}\text{S}]$ GTP γ S functional assays results












Figure S1. Dose-response curves for $[^{35}\text{S}]$ GTP γ S binding *versus* ligand concentration.












12. Computational pharmacokinetic parameters














According to different authors and different databases⁷ CNS drugs already in the market show the following physicochemical characteristics: MW less than 400 with a mean value of 310 g mol⁻¹, (c)logP less than 5 with a preferred value around 1.5-2.7, 2.5 or 3.43 (depending on the authors), (c)logD_{7.4} greater than 0 and less than 3 (optimum value 2.1), total PSA in the range 40-90 Å² and pK_{aH} between 7.5–10.5.









Table S3. Calculated physicochemical properties [Molecular weight (MW), total polar surface area (PSA), Partition coefficient (logP), Distribution coefficient (logD) and basicity (pK_{aH})].of all the compounds studied (and some benzene analogues highlighted in blue, for comparison) obtained from MarvinSketch. Counterions were not considered. Italicised values are within the desired range for CNS-acting drugs.

Comp.	Structure	MW	PSA (Å ²)	logP	logD (pH 7.40)	pK _{aH}
5c		<i>137.17</i>	76.5	0.3	-1.6	9.5
		<i>135.17</i>	<i>61.9</i>	0.9	-1.4	11.5
11c		<i>137.17</i>	76.5	-0.3	-2.5	10.1
6c		<i>216.06</i>	76.5	1.1	-0.4	9.0
7c		<i>171.61</i>	76.5	0.9	-0.6	9.0
		<i>169.61</i>	<i>61.9</i>	1.5	-0.7	10.9

12c		171.61	76.5	0.6	-1.5	9.6
8c		151.19	76.5	0.8	-1.1	9.5
9c		191.26	76.5	1.7	-0.2	9.3
		189.26	61.9	2.4	0.1	10.6
14c		191.26	76.5	1.1	-1.1	9.9
10c		180.23	88.6	0.2	-1.9	9.7
		178.23	73.9	0.8	-1.6	10.9
15c		180.23	88.6	0.2	-2.1	10.3
13c		151.19	76.5	-0.1	-2.4	10.1
17c		182.16	119.7	0.3	-0.6	8.2
18c		152.18	102.5	-0.5	-2.6	9.8

5d		163.20	50.9	0.7	-0.7	8.7
		161.20	36.4	1.3	-1.0	10.1
7d		197.65	50.9	1.3	0.4	8.2
8d		177.23	50.9	1.2	-0.1	8.7
9d		217.30	50.9	2.0	0.9	8.5
10d		206.27	63.0	0.5	-0.9	8.8
11d		163.20	50.9	0.1	-1.8	9.3
14d		217.30	50.9	1.4	-0.2	9.1
		215.29	36.4	2.7	0.7	9.7
15d		206.27	63.0	0.5	-1.4	9.4
		204.27	48.5	1.1	-1.1	10.1



5i		213.26	62.5	2.5	1.8	8.7
8i		227.29	62.5	3.0	2.3	8.6
9i		267.36	62.5	3.8	3.3	8.5
		265.35	47.9	4.6	3.0	9.1
5j		181.22	82.8	-0.1	-2.0	9.0
8j		195.25	82.8	0.4	-1.5	9.0
9j		235.31	82.8	1.2	-0.5	8.8
5k		217.25	75.7	1.4	-0.2	8.6
8k		231.28	75.7	1.9	0.3	8.6
		229.28	61.1	2.5	0.2	10.3
9k		271.34	75.7	2.7	1.3	8.4
7l		213.69	62.5	2.1	0.3	8.8
		211.69	47.9	2.7	0.4	10.6

8l		193.27	62.5	2.0	-0.1	9.4
19i		224.29	38.0	3.1	2.1	8.4
19j		192.24	58.3	0.5	-1.4	9.5
20j		193.23	71.2	-0.1	-0.9	8.2
19k		228.27	51.2	2.0	0.2	9.3
20k		228.26	62.5	1.4	0.7	9.1
19l		190.27	38.0	2.1	-0.2	10.2
20m		283.31	69.4	2.3	1.0	8.3

All of our compounds have molecular weights below 285 g mol⁻¹ (average MW = 198.7 g mol⁻¹), average ClogP around 1.2 (only one compound with a value > 3.1 and six compounds with values < 0.2) and logD_(7.4) values < 3.2, making them suitable for CNS penetration. The majority of our compounds are within the desired range of total PSA (only two exceptions with values ~100-120), while the pK_{aH} limits of 7.5-10.5 are obeyed by all compounds (the average value being 9.1). These molecules do not contain acidic protons, an undesirable feature that leads to high plasma protein binding and low brain penetration, and are protonated at physiological pH.

We have also calculated the same properties for the benzene analogues of a selection of the compounds studied (highlighted in blue in Table S3). In all the cases MW and PSA are very similar. Regarding lipophilicity (logP and logD) in most of the cases does not make any substantial difference and only in a couple of cases the benzene derivatives have better lipophilicity (highlighted in green) for CNS absorption while in another cases the increment in lipophilicity is detrimental (highlighted in yellow). The biggest difference observed between both series is in terms of basicity. The pK_a of the benzene analogues is around one unit larger than that of the pyridine compounds, that means that the benzene analogues are more basic and this can be detrimental (highlighted in yellow) for CNS absorption since the acceptable rage is 7.5-10.5.

Activation of hERG is the responsible of secondary cardiac effects of many potential drugs. Recently, a ligand-based pharmacophore for the activation of hERG channels has been developed (and experimentally validated) using the Catalyst software;⁸ in order to evaluate if our compounds fulfil such a pharmacophore, and hence produce cardiopathies, we have computationally optimised (DFT level: B3LYP/6-31+G*, PCM-water) four of them (**8l**, **9c**, **9i** and **14d**). The optimised structures indicating the pharmacophoric elements common to the Catalyst pharmacophore developed elsewhere, as well as the Catalyst pharmacophore are shown in Figure S2.



Catalyst pharmacophore developed by Kratz et al.

Figure S2.- Optimised structures calculated at B3LYP/631+G* PCM(water) and Catalyst pharmacophore developed by Kratz et al.

The four Catalyst pharmacophoric elements of Kratz *et al.* are: a positively ionisable group, two hydrophobic groups and a hydrophobic aromatic group. We found that compound **9c** does not present one of the two hydrophobic groups and even though compounds **8l**, **9i** and **14d** present all four pharmacophoric elements, the distances between these elements are not those of the Catalyst pharmacophore. Hence, these compounds do not fulfil the pharmacophore, would not be able to block the hERG channel and, in principle, would not show cardiotoxicity.

Table S4. Distances (Å) between the pharmacophoric elements of the Catalyst pharmacophore developed by Kratz and those found for our compounds **8l**, **9c**, **9i** and **14d**. In italics/bold are those distances that do NOT fulfil the Catalyst pharmacophore (considering a margin of ± 0.9 Å).

	Catalyst Pharm.	8l	9c	9i	14d
Positively ionisable -Hydrophobic(1)		[Me]		<i>[(CH₂)₄]</i>	<i>[(CH₂)₄]</i>
	6.90	6.61 (C+)	6.58-7.14 (C+)	6.57-7.13 (C+)	6.54-7.21 (C+)
Positively ionisable -Hydrophobic(2)		[Pr]		[Ph]	[Im(CH ₂) ₂]
	5.87	5.00 (C+)	-	3.81 (C+)	2.31 (C+)
Positively ionisable -Hydrophobic Ar		6.83	3.76 (C+)	3.89 (C+)	3.75 (C+)
Hydrophobic (1) - Hydrophobic Ar			[Me]	<i>[(CH₂)₄]</i>	<i>[(CH₂)₄]</i>
	3.63		2.97	3.70	3.78
Hydrophobic (2) - Hydrophobic Ar			[Pr]	[Ph]	[Im(CH ₂) ₂]
	7.56		7.31	6.73	5.23-5.84
Hydrophobic (1) - Hydrophobic (2)		9.43	9.16	7.85-8.90	8.64-9.40

13. Molecular Modelling















The sequences of the human α_{2A} -AR (P18825) and α_{2A} -AR (P08913) were obtained from the uniprot database. The Modeller V9.12 software was used to generate five most probable structures based on three templates of the homologous β_2 -AR (2R4S^{Error! Bookmark not defined.} 3D4S^{Error! Bookmark not defined.} and 3SN6^{Error! Bookmark not defined.}). The sequence homology for the α_{2A} -AR was 38.9%, while for the α_{2C} -AR it was 35.2%. Comparing their DOPE (Discrete optimized protein energy) score and GA431 score, the most suitable model was selected. This model was also validated by its Ramachandran plot to ensure no highly unfavoured arrangements existed. Then, the model was solvated in explicit TIP3P water in the AMBER software^{Error! Bookmark not defined.} and further refined by a three-step minimisation procedure: Initially all ions and solvent molecules were relaxed with the protein constrained, then the solvent, ions and amino-acid side-chains were relaxed, and finally the entire system was minimized to give the structure which was used for docking simulations using the MOE.2010 software.^{Error! Bookmark not defined.} The 3SN6 crystal structure was chosen to identify the ligand binding site applied for docking as it contains an agonist in its orthosteric site which has activated the GPCR (amino acids within 4.5 Å were included in the site).













The ligands were built in MOE and minimized using the CHARMM27 force field with a 0.05 gradient. A full conformational search was conducted using the LowModeMD⁹ method with a RMS gradient of 0.005, a strain cut-off of 10 kcal mol⁻¹ and a minimum of 100 iterations, to generate approximately 60 conformations per ligand. The generated conformers were docked into the relevant receptors in MOE using the triangle matcher placement method and the London dG scoring function.³⁰ A post placement molecular mechanics forcefield refinement was carried out on the top 30 poses in which side chains of the protein were free to move and a non-interacting cut-off of 12 Å was applied. The final docking energy (E-refine) was calculated using the GB/VI solvent model.¹⁰

Table S5 shows the docking scores for all compounds in the α_{2A} -AR and α_{2C} -AR models, as well as their experimental binding affinity expressed as pK_i. The interactions established to form the complexes between the compounds studied and the respective binding sites illustrate the likely requirements for interacting at these receptors with high affinity.

Table S5. Compounds examined by molecular docking in homology models of the α_{2A} -AR and α_{2C} -AR, with their pK_i values and docking scores (kcal mol⁻¹).

Comp.	Structure	pK_i	$S \alpha_{2A}\text{-AR}$ (kcal mol ⁻¹)	$S \alpha_{2C}\text{-AR}$ (kcal mol ⁻¹)
5c		6.19	-6.81	-7.23
6c		5.62	-7.31	-7.75
7c		5.70	-6.94	-7.40
8c		6.03	-7.13	-7.57
9c		6.78	-7.15	-8.86
10c		4.12	-7.39	-8.58
11c		3.79	-6.84	-7.07
12c		5.18	-7.30	-7.33
13c		4.97	-7.66	-7.45
14c		5.57	-7.11	-8.27
15c		6.35	-7.62	-8.22
17c		5.00	-6.84	-8.13
18c		5.00	-6.55	-7.41

5d		6.44	-7.11	-7.85
7d		6.25	-7.10	-8.04
8d		6.41	-7.17	-8.24
9d		6.27	-8.02	-9.27
10d		5.65	-7.99	-8.66
11d		5.28	-6.69	-7.82
14d		7.02	-8.03	-9.43
15d		7.13	-8.04	-8.73
5i		6.21	-8.08	-9.32
8i		6.02	-8.34	-9.80
9i		6.75	-9.04	-10.31
5j		5.38	-7.60	-8.22
8j		5.21	-7.62	-8.91
9j		5.83	-7.98	-10.06

5k		6.32	-7.91	-9.22
8k		6.28	-8.52	-9.80
9k		6.67	-9.15	-9.91
7l		5.71	-7.88	-8.88
8l		6.74	-7.85	-9.65
19i		4.40	-8.04	-9.36
19j		6.26	-7.06	-8.63
19k		5.35	-8.41	-9.38
19l		4.33	-7.21	-8.76
20j		4.49	-7.60	-8.63
20k		4.50	-8.44	-9.51
20m		5.30	-9.25	-9.60

Homology model

>sp|P08913|ADA2A_HUMAN Alpha-2A adrenergic receptor OS=Homo sapiens
GN=ADRA2A PE=1 SV=3

MGSLQP DAGNA SWNG TEAP GGGARAT PYSLQV TLV CLAG LMLL TVFG NVLVII
 AVFTSR ALKAPQ NLFLV SLASAD ILVATL VIPS LANE VMGY WYFG KAWCEI YLALD
 VLFCTSSIVHLCAISLD RYWSITQAIEYNLKRTPRRIKAIITVWVISA VSFPLISIEKK
 GGGGGPQPAEPRCEINDQK WYVISSCIGSFFAPCLIMILVYVRIYQIAKRRTRVPPSRR
 GPDAVAAPPGGTERRPNGLGPERSAGPGGAEAEPLPTQLNGAPGEPA PAGPRDTDAL
 DLEESSSSDHAERPPGPRRPERGPRGKGKARASQVKPGDSLPRRGPGATGIGTPAAGP
 GEERVGAAKASRWGRQNREKRTFVLAVVIGVFVVCWFPPFTYTLTAVGCSVPR
 TLFKFFFWFGYCNSSLNPVIYTI FNHDFRRAFKKILCRGDRKRIV

>sp|**P18825**|ADA2C_HUMAN Alpha-2C adrenergic receptor OS=Homo sapiens
 GN=ADRA2C PE=2 SV=2

MASP ALAA ALAVAA AAGPNASGAG ERGSGGVANASGASWGPPRGQYSAGA VAGL
 AAVVGFLIVFTVVG NVL VVIAV L TSRALRAPQ NLFLV SLASAD ILVATL VMPF SLANE
 LMAYWYFGQVWCGVYLALDVL FCTSSIVHLCAISLD RYWSVTQAVEYNLKRTPRR
 VKATIVAVWLISA VSFPLVSLYRQPDGAA YPQC GLNDET WYI LSSCIGSFFAPCLIM
 GLVYARIYRVAKLRT RTLSEKRAPVGP DGASPTT ENGLGAAAGAGENGHCAPPAD
 VEPDESSAAAERRRRRGALRRGGRRAGAEGGAGGADGQGAGPGAAESGALTASR
 SPGPGGRLSRASSRSVEFFLSRRRRARSSVCRRKVAQAREKRTFVLAVVMGVF VLC
 WFPFFFSYSLY GICREACQVPGPLFKFFFWIGYCNSSLNPVIYTVFNQDFRRSFKHILF
 RRRRRGFRQ

Models generated by Modeller:


Alpha 2a	molpdf	DOPE	GA431
		Score	Score
query.B99990001.pdb	11807.35	-46242.20	1.00
query.B99990002.pdb	11759.67	-46738.02	1.00
query.B99990003.pdb	12039.37	-46161.49	1.00
query.B99990004.pdb	11827.11	-46195.85	1.00
query.B99990005.pdb	11823.14	-46350.15	1.00
Seq ID	38.89%		
Alpha 2c	molpdf	DOPE	GA431
		Score	Score

query.B99990001.pdb	17689.31	-42877.41	0.36
query.B99990002.pdb	17731.83	-43870.66	0.51
query.B99990003.pdb	18312.22	-43908.57	0.25
query.B99990004.pdb	18245.95	-42806.20	0.44
query.B99990005.pdb	18349.35	-43115.01	0.44
Seq ID	35.19%		


DOPE profile of **query.B99990002.pdb** of the α_{2A} -AR overlaid with that of templates.




DOPE profile of **query.B99990002.pdb** of the α_{2C} -AR overlaid with that of templates.



Ramachandran plot of **query.B99990002.pdb** of the α_{2A} -AR.



Ramachandran plot of **query.B99990002.pdb** of the α_2 A-AR.



Docking to α_2 C-AR and α_2 A-AR

Binding site identification:

Using the 3SN6 crystal structure and the site view tool in MOE, the ligand “site” amino acids were identified. This was extrapolated to the homology model by aligning the homology models with 3SN6. Residues with identical homology are highlighted green.

3SN6	α_2 A-AR model
W 239	Y 109
T 240	L 110

D 243	D 113
V 244	V 114
V 247	C 117
T 248	T 118
C 318	C 188
D 319	E 189
F 320	I 190
Y 326	Y 196
A 327	V 197
S 330	S 200
S 331	C 201
S 334	S 204
W 388	W 387
F 391	F 390
F 392	F 391
N 395	Y 394
K 407	R 405
Y 410	F 408
I 411	K 409
N 414	F 412
Y 418	Y 416

The corresponding amino acids were then used to define the site for docking of compounds into the homology model of the α_{2A} -AR.

The same strategy was employed for the docking of ligands into the α_{2C} -AR.

3SN6	α_{2C}-AR model
W 239	-
T 240	L 128
D 243	D 131
V 244	V 132
V 247	C 135

T 248	T 136
C 318	C 202
D 319	G 203
F 320	L 204
Y 326	Y 210
A 327	I 211
S 330	S 214
S 331	C 215
S 334	S 218
W 388	W 395
F 391	F 398
F 392	F 399
N 395	Y 402
K 407	G 416
Y 410	F 419
I 411	K 420
N 414	F 423
Y 418	Y 427

There is 57.3% identity between the sequences of the α_{2A} -AR and the α_{2C} -AR.

1. D. H. O' Donovan, I. Rozas, *Tet. Lett.*, **2011**, 52, 4117-4119.
2. P. K. Mohanta, S. Dhar, S. K. Samal, H. Illa, H. Junjappa, *Tetrahedron*, **2000**, 56, 4, 629-638.
3. R. J. Vijn, H. J. Arts, P. J. Maas, A. M. Castelijns, *J. Org. Chem.*, **1993**, 58, 887-891.
4. Y. Tohda, M. Eiraku, T. Nakagawa, Y. Usami, M. Ariga, T. Kawashima, K. Tani, H. Watanabe, Y. Mori, *Bull. Chem. Soc. Jpn.*, **1990**, 63, 2820-2827.

5. C. Dardonville, P. Goya, I. Rozas, A. Alsasua, I. Martín, J. Borrego, *Bioorg. Med. Chem.*, **2000**, 8, 1567-1577.
6. P. Das, C. K. Kumar, K. N. Kumar, M. Innus, J. Iqbal, N. Srinivas, *Tet. Lett.*, **2008**, 49, 992-995.
7. Pajouhesh, P.; Lenz, G.R. Medicinal Chemical Properties of Successful Central Nervous System Drugs. *NeuroRx*, **2005**, 2, 541-553.
8. Kratz, J. M.; Schuster, D.; Edtbauer, M.; Saxena, P.; Mair, C. E.; Kirchebner, J.; Matuszczak, B.; Baburin, I.; Hering, S.; Rollinger, J. M. Experimentally Validated hERG Pharmacophore Models as Cardiotoxicity Prediction Tools. *J. Chem. Inf. Model.*, **2014**, DOI: 10.1021/ci5001955
- ⁹. Labute, P. LowModeMD—Implicit Low-Mode Velocity Filtering Applied to Conformational Search of Macrocycles and Protein Loops. *J. Chem. Inf. Model.*, **2010**, 50, 792-800.
- ¹⁰. Labute, P. The generalized Born/volume integral implicit solvent model: Estimation of the free energy of hydration using London dispersion instead of atomic surface area. *J. Comput. Chem.*, **2008**, 29, 1693-1698.